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EFFECTS OF HUMAN OBESITY-ASSOCIATED MUTATIONS ON 
CELLULAR ACTIONS OF THE ADAPTER PROTEIN SH2B1 
By 
Michael E. Doche 
Chair:  Christin Carter-Su 
 
Src homology 2 B adapter protein 1 (SH2B1) modulates signaling by a 
variety of ligands that bind to receptor tyrosine kinases or JAK-associated 
cytokine receptors, including leptin, insulin, growth hormone (GH), and nerve 
growth factor (NGF).  Targeted deletion of Sh2b1 in mice results in increased 
food intake, obesity, and insulin resistance.  SH2B1 is expressed as four different 
isoforms: alpha, beta, gamma, and delta.  SH2B1 loss-of-function mutations were 
identified in a cohort of patients with severe early-onset obesity.  Mutation 
carriers exhibit hyperphagia, childhood-onset obesity, disproportionate insulin 
resistance, and reduced final height as adults.  Unexpectedly, mutation carriers 
also exhibit a spectrum of behavioral abnormalities that were not reported for 
 xii 
controls, including social isolation and aggression.  The work in this thesis 
characterizes cellular functions of SH2B1 alpha, beta, and delta and examines 
how human mutations in SH2B1 affect their functions.  SH2B1beta with a human 
mutation exhibits an impaired ability to enhance NGF-induced neurite outgrowth, 
accumulate in the nucleus, and enhance GH-induced macrophage migration.  In 
contrast to SH2B1beta, SH2B1alpha does not enhance NGF-induced neurite 
outgrowth or uPAR mRNA expression and does not cycle through the nucleus.  
SH2B1delta has a sub-cellular localization at the plasma membrane and 
nucleolus.  A bipartite nuclear localization signal (NLS) in the unique C-terminal 
tail of SH2B1delta is important for its nucleolar localization and enhancement of 
NGF-induced neurite outgrowth.  SH2B1delta with a disease-causing human 
mutation does not enhance NGF-induced neurite outgrowth to the same extent 
as SH2B1delta WT.  Thus, the ability of SH2B1 isoforms to promote neuronal 
differentiation and cell migration may contribute to the control of human food 
intake and body weight and is implicated in maladaptive human behavior.  To 
translate results from PC12 cells to a GH context, SH2B1, including its NLS 
region, was shown to be required for the enhancement of expression of a sub-set 
of GH-induced genes.  Taken together, these results highlight the importance of 
understanding how the different isoforms of SH2B1 regulate gene transcription, 
cell motility, and neuronal differentiation to promote whole-body energy 








The Genetics of Obesity Study and Monogenic Causes of Obesity 
 
Many years of a sedentary lifestyle along with over-consumption of high 
calorie foods are believed to be main factors contributing to a growing obesity 
epidemic in developed Western countries.  However, these factors alone cannot 
be responsible for severe, early-onset obesity, or obesity seen in children (1).  It 
has been thought that the main factors contributing to obesity in children must 
have a genetic component since children have not had the years of imbalanced 
energy intake to develop obesity as seen in adults.  Many genetic consortiums 
have been established to identify genetic markers that may be contributing to 
human disease.  One such consortium that was established in 1997 is the 
Genetics of Obesity Study (GOOS) (2).   The aim of this consortium is to recruit 
patients with severe obesity [body mass index (BMI) sd score (SDS) > 3] of early 
onset (<10 years old), particularly children with a strong family history of obesity 
and those from consanguineous families. With the help of researchers and 
clinicians throughout the world, this consortium has to date recruited over 4500 
patients to the GOOS cohort.  In the past several years, GOOS and other 
research groups have described many human disorders of energy balance that 
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arise from genetic defects (3).  All of these are in molecules identical or similar to 
those known to cause obesity in genetic and experimental syndromes of obesity 
in rodents, and all have been identified using a candidate gene approach. These 
mutations all result in severe obesity in childhood without developmental 
pleiotropic features.  Many of the mutations that result in obesity encode genes 
for leptin, leptin receptor, or proteins involved in the transduction of the leptin 
signal in the central nervous system.   
 Leptin is an adipocyte-derived hormone that interacts with leptin receptors 
in neurons in the brain, particularly the arcuate nucleus and other regions of the 
hypothalamus, to influence whole-body energy homeostasis (4, 5).  Leptin is 
found in the circulation at levels proportionate to body-fat content and acts to 
maintain energy balance by reducing appetite and increasing thermogenesis (6).  
When leptin signaling is disrupted, individuals do not feel sated after a meal and 
constantly seek food consumption.  This pathological level of food intake is 
termed hyperphagia.  Early studies have identified several individuals and 
families with mutations in the genes encoding leptin or the leptin receptor that 
suffer from obesity caused by hyperphagia (7-10). 
 Leptin receptor-expressing neurons project to groups of neurons within the 
hypothalamic arcuate nucleus that are critical to the regulation of food intake and 
energy balance.  One group are pro-opiomelanocortin (POMC) neurons that 
produce α-MSH (melanocyte stimulating hormone) that is anorectic and another 
are neurons that express the orexigenic factors neuropeptide Y (NPY) and 
agouti-related protein (AGRP) (11).  AGRP is an antagonist of MC3R and MC4R 
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(melanocortin 3 and 4 receptors), which act downstream of POMC neurons.  
Leptin regulates these neuronal populations in a reciprocal manner; it activates 
POMC neurons and inhibits NPY/AGRP neurons to decrease food intake and 
increase energy expenditure (12).  Genetic variations that lead to deficiencies in 
POMC or MC4R expression or activity have been identified in patients with 
severe, early-onset obesity caused by hyperphagia (reviewed in (3) and (2)).  
Additional mutations in children with severe obesity have been identified in the 
genes encoding brain-derived neurotrophic factor (BDNF) and its receptor, 
tyrosine kinase TrkB (13-15).  BDNF is important for development, survival, and 
differentiation of neurons (16).  Recently, investigators have seen that leptin-
stimulated neural activity induces dendritic BDNF synthesis, which is important 
for transducing the neural leptin signal required to promote nutritional satiety 
(17).  Thus, human mutations that disrupt the neuro-endocrine signaling of leptin 
cause hyperphagic obesity. 
 The adapter protein SH2B1 (which will be discussed more thoroughly later 
in this report) is important for mediating leptin signal transduction (18, 19).  The 
long form of the leptin receptor interacts with the receptor-associated tyrosine 
kinase JAK2 to initiate intracellular signal transduction (20, 21).  SH2B1 has been 
reported to interact with and potentiate the activation of JAK2 (22, 23).  In 
response to leptin, SH2B1 binds to phospho-tyrosine 813 in JAK2 and not only 
enhances total JAK2 activity (which globally enhances the leptin signal) but also 
enhances recruitment insulin receptor substrate 1 (IRS1) to be phosphorylated 
by JAK2 and activate the downstream phosphatidylinositol 3-kinase (PI3K) 
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pathway (19).  This evidence shows that SH2B1 is an important positive 
regulator of leptin signal transduction.  As with mutations in other genes that 
mediate the leptin signal, dysfunction-causing mutations in SH2B1 would be 
expected to lead to leptin resistance and hyperphagic obesity in humans.  The 
effects on the cellular actions of SH2B1 of human obesity-associated mutations 






















The Adapter Protein SH2B1 
 
 Adapter proteins are important signaling molecules that usually do not 
have enzymatic capabilities of their own, but rather function to link enzymatic 
proteins with their substrates to facilitate the enzymatic reaction.  Adapter 
proteins play a role in signal transduction from ligand-stimulated receptor or 
receptor-associated tyrosine kinases.  Ligand binding activates tyrosine kinase 
enzymatic activity producing phospho-tyrosine residues that can serve as 
docking sites for proteins with Src homology 2 (SH2) or phosphotyrosine binding 
(PTB) domains (24).  Adapter proteins usually consist of multiple protein-protein 
interaction domains (including SH2 or PTB domains) to link signaling molecules 
in a complex to facilitate the transduction of the extracellular signal.  One group 
of adapter proteins that play a role in various signaling pathways is the SH2B 
family.  There are three members of the SH2B family: SH2B1 (formerly named 
SH2-B, also known as PSM), SH2B2 (formerly named APS) and SH2B3 
(formerly named Lnk).  These proteins share a common domain structure 
consisting of a dimerization domain, proline rich domains, a PH domain and a 
SH2 domain and were first identified as proteins involved in immune cell 
activation signaling (25-27).  There have been four SH2B1 isoforms, produced by 
variable mRNA splicing, identified.  The four isoforms, termed alpha, beta, 
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gamma, and delta, are identical in sequence except for the region downstream of 
the SH2 domain splice sites.  Variable mRNA splicing confers unique C-terminal 
sequences for each isoform (28, 29) (FIG. 1.1).   
SH2B1 has been identified as having a role in the signal transduction 
process for several receptor tyrosine kinases, including the receptors for NGF 
(30, 31), insulin (32, 33), insulin-like growth factor I (IGF-I)(34), brain-derived 
neurotrophic factor (BDNF) (30), glial cell line-derived neurotrophic factor 
(GDNF)(35), platelet-derived growth factor (PDGF)(36), and fibroblast growth 
factor (FGF)(37).  SH2B1 has also been seen to play role in signaling for the JAK 
family of receptor-associated tyrosine kinases (22, 23, 38).   
 The mechanism by which SH2B1 interacts with JAK2 and mediates its 
signal transduction has been investigated in detail.  SH2B1 acts to enhance 
JAK2 activation and autophosphorylation while also recruiting proteins to active 
JAK2 to mediate activation of signaling pathways.  One proposed mechanism of 
how SH2B1 enhances JAK2 activity is that dimerization of SH2B1 leads to 
dimerization of its associated JAK2, which then enhances JAK2 activity (38).  
Another proposed mechanism is that SH2B1 binds to an already active (and 
autophosphorylated) JAK2 to cause a conformational change that maintains 
JAK2 in an active state (39).  The latter is supported by the results that only the 
SH2 domain of SH2B1β and only one SH2B1β needs to be bound to a JAK2 
dimer to increase the activity of JAK2.  Both models agree, though, that SH2B1 
directly functions to increase JAK2 activity and does not compete with an 
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inhibitor or recruit an activator to potentiate JAK2 activity.  It has been shown that 
SH2B1β  
  
  SH2B1  splice  variants  
are  identical  in  sequence  
except  for  their  C-­termini  
  
Maures  et  al.  2007  
DD  
NLS1   NES  
PH   SH2  
P   P  
670  
DD  
NLS1   NES  
PH   SH2  




25   85   152  146  
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FIG. 1.1. Schematic representation of the four isoforms of SH2B1. P = 
Proline-rich region, DD = Dimerization Domain, NLS = Nuclear Localization 
Sequence, NES = Nuclear Export Sequence, PH = Plextrin homology, SH2 = 
Src Homology 2 domain, arrow = Variant splice site.  Isoform-specific C-terminal 
regions indicated by unique color. 
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binds to phospho-tyrosine 813 that lies in an YXXL motif in the pseudokinase 
domain (JH2) of JAK2 (40).  The JH2 domain is thought to be an autoinhibitory 
region of JAK2 that blocks the JH1 kinase domain and becomes displaced upon 
ligand binding to allow for JH1 kinase domain activity to the associated receptor 
(41).  JAK2 has also been seen to phosphorylate SH2B1β on tyrosines 439 and 
494 (42).  Growth hormone (GH) is able to stimulate actin cytoskeletal 
rearrangement, membrane ruffling, and cell motility.  SH2B1β WT, but not 
SH2B1β with mutated tyrosines 439 and 494, is able to potentiate this effect (42-
44).  SH2B1β is thought to elicit this effect at least in part by recruiting the actin 
cytoskeleton regulator Rac to GH-activated JAK2/GH receptor complexes.  The 
effects of GH on actin dynamics and cell motility are blunted when SH2B1 cannot 
interact with Rac (45).  Thus, SH2B1 acts to enhance signal transduction from 
JAK2 by binding to JAK2 and maintaining it in a more active confirmation and by 
recruiting effector proteins to active JAK2 at the plasma membrane.  
 The role of SH2B1 in insulin signaling has been investigated in vitro and in 
vivo.  SH2B1 binds to phospho-tyrosines in the activation loop of the insulin 
receptor (IR) via its SH2 domain and is tyrosyl phosphorylated (32, 33, 46, 47).  
SH2B1 enhances IR activity and cellular responses, including mitogenesis and 
glucose uptake (48, 49).  Expression of SH2B1 stimulates IR activity leading to 
increased IRS phosphorylation and PI3K signaling, as well as extracellular 
regulated kinase (ERK) signaling (50, 51).  SH2B1 expression delays 
dephosphorylation of IR and IRS (50) and protects IRS from phosphatases (51).  
In mice, deletion of Sh2b1 impairs insulin receptor activation and signaling in the 
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liver, skeletal muscle, and adipose tissue leading to the development of 
hyperinsulinemia, hyperglycemia, and glucose intolerance (52, 53).  Thus, 
SH2B1 has been implicated as an important mediator of insulin signaling and is 
required for maintaining normal insulin sensitivity and glucose homeostasis. 
SH2B1 has been implicated in the regulation of whole-body energy 
homeostasis.  The SH2B1-/- mice generated by Ren et al. display hyperphagia 
and obesity (18).   Plasma leptin levels in these mice were elevated before the 
onset of obesity, suggesting that systemic leptin resistance is a primary 
contributing factor to the obesity rather than a symptom.  As mentioned 
previously, SH2B1-/- mice displayed age-dependent glucose intolerance, 
hyperglycemia, and hyperinsulinemia (52), consistent with SH2B1 being a 
positive regulator of insulin signaling.  However, when SH2B1 is transgenically 
expressed only in neurons in SH2B1-/- mice, the hyperleptinemia, obesity, and 
insulin resistance are rescued (54).  This phenotype suggests that only neuronal 
SH2B1 is required to reverse the metabolic disorder seen in SH2B1-whole body 
KOs.  A second group has also generated SH2B1-/- mice but did not report 
development of an obese phenotype (55).  They concluded that their SH2B1-/- 
mice remained lean because SH2B1 is a critical positive regulator of 
adipogenesis by mediating insulin/IGF-1 signaling (56).  It is hypothesized that 
differences in diet and environmental stress can possibly account for the 
discrepancies in phenotype (18).  However, both groups shared findings of 
infertility and neonatal growth retardation between 2-6 weeks of birth, consistent 
with SH2B1 playing a role in GH and IGF-1 signaling. 
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There has been a growing body of evidence implicating a role for SH2B1 
in neurotrophic function, including neuronal differentiation and TrkA signaling.  
Yeast two-hybrid screens identified SH2B1 (later identified to be the gamma 
isoform by unpublished observation from the Carter-Su Lab) and SH2B2 as 
interacting partners of TrkA via phosphorylated tyrosines in the kinase activation 
loop (30).  GST pull down assays confirmed the phospho-tyrosine dependent 
interaction between SH2B1β and TrkA as the interaction was only seen using 
cells that had been treated with NGF.  It was not seen when SH2B1β with an 
inactivating mutation in the SH2 domain was employed (31), suggesting that the 
interaction with TrkA requires an intact SH2 domain.  SH2B1β becomes tyrosyl 
phosphorylated in response to NGF and is recruited to active TrkA.  Similarly, 
Shc and phospholipase C (PLC)-γ are also recruited to activated TrkA and 
phosphorylated in response to NGF (30, 31, 57-59).  While TrkA phosphorylation 
of PLC-γ initiates its enzymatic activity (60), tyrosyl phosphorylation of SH2B1 is 
assumed to create docking sites for protein complex formation at the receptor to 
mediate signal transduction cascades, similar to the adapter protein Shc when 
tyrosyl phosphorylated by active TrkA.  Tyrosyl phosphorylated Shc recruits 
Grb2-SOS complexes which leads to the activation of the Ras-ERK signaling 
cascade (59, 61).  SH2B1 has also been seen to interact with Grb2 (30), 
suggesting SH2B1 may play a similar role as Shc in NGF signaling. 
SH2B1 promotes neuronal survival and differentiation.  Rat neonatal 
sympathetic neurons cultured with NGF had greatly reduced survival rates when 
anti-SH2B1 antibodies were introduced intracellularly to reduce the activity of 
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endogenous SH2B1.  Sympathetic neurons also exhibited axonal degeneration 
when transfected with cDNA encoding a truncated SH2B1 mutant.  In contrast, 
overexpression of cDNA encoding SH2B1 WT promoted long, branched axonal 
outgrowths (30).  Overexpression of SH2B1 enhances NGF-induced neurite 
outgrowth in PC12 cells (the sympathetic neuron-like PC12 cell line will be 
described later in this chapter), while shRNA-mediated knockdown of 
endogenous SH2B1 significantly decreased NGF-induced neurite outgrowth (62).  
Partially conflicting mechanisms by which SH2B1 mediates these effects have 
been reported, which may be a result of which SH2B1 isoform was used in the 
investigations.  Overexpression of SH2B1γ in PC12 cells led to heightened and 
prolonged TrkA tyrosine phosphorylation as well as heightened and prolonged 
phosphorylation of ERKs 1/2 (63).  Qian et al. concluded that SH2B1 promotes 
neuronal differentiation as a consequence of increasing the activity of TrkA and 
the ability of SH2B1 to recruit Grb2 to initiate Ras-dependent signaling, leading to 
increased and prolonged ERK 1/2 phosphorylation levels.  However, other 
evidence suggests that SH2B1β may promote neuronal differentiation through a 
different mechanism.  While SH2B1β enhanced and SH2B1β(R555E) inhibited 
neuronal differentiation in PC12 cells, neither was seen to alter NGF-induced 
TrkA autophosphorylation or phosphorylation of downstream signaling proteins 
like ERKs 1/2 (31).  These results suggest that SH2B1β may not be directly 
affecting TrkA activation and could be regulating NGF-induced neuronal 
differentiation through a pathway parallel or downstream of ERKs 1/2.   
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SH2B1 plays a role in mediating signaling for other neurotrophic factors 
such as BDNF and GDNF.  SH2B1 binds to active TrkB and is phosphorylated in 
response to BDNF (30, 64).  SH2B1 also interacts with RET, the receptor for 
GDNF, and facilitates GDNF-induced neurite outgrowth in PC12 cells and 
mesencephalic neurons (35).  These findings implicate SH2B1 in having a 
broader role in neurotrophic signaling and neuronal development.  
While investigating the mechanism by which SH2B1β enhances NGF-
induced neuronal differentiation, it was discovered that SH2B1β is capable of 
localizing in the cell nucleus.  Although microscopy images show a steady-state 
localization of SH2B1β WT at the PM or cytosol (65), inhibition of Crm1-mediated 
nuclear export with leptomycin B caused SH2B1β to accumulate in the nucleus 
(66).  Chen et al. identified a nuclear-export sequence (NES) in SH2B1 that when 
mutated or deleted also causes SH2B1β to accumulate in the nucleus (66).  
SH2B1β without a functional NES is unable to enhance NGF-induced PC12 cell 
differentiation (66).  Further investigation identified a nuclear localization signal 
(NLS) in SH2B1β and mutation of this NLS also abolishes the ability of SH2B1β 
to enhance NGF-induced neuronal differentiation in PC12 cells (62).  The NLS of 
SH2B1β, along with the dimerization domain, has also been shown to be 
required for SH2B1β to localize to the PM (65).  Phosphorylation of serine 
residues proximal to the NLS (primarily Ser161 and Ser165) is necessary for 
SH2B1β to be released from the PM and translocate to the nucleus to enhance 
NGF-induced neurite outgrowth (65).  These data suggest that while SH2B1β 
has a steady-state sub-cellular localization at the PM and cytosol, it is 
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constitutively shuttling in and out of the nucleus.  Further, this nucleo-cytoplasmic 
cycling is required for SH2B1β to be able to enhance NGF-induced neuronal 
differentiation.   
Subsequent investigation into the nuclear role of SH2B1 in NGF-induced 
neuronal differentiation was conducted.  Microarray analysis of NGF-treated (100 
ng/ml for 6 hours) PC12 cells expressing SH2B1β WT or the dominant-negative 
SH2B1β (R555E) revealed a sub-set of NGF-induced genes that require SH2B1β 
for their full NGF-induced expression (67).  Among this sub-set, some of the most 
highly NGF and SH2B1β regulated genes were Plaur, Mmp3, and Mmp10, which 
encode the proteins urokinase plasminogen activator receptor (uPAR), matrix 
metalloproteinase 3 (MMP3), and MMP10, respectively.  These proteins are 
involved in the same extracellular matrix degradation pathway important for 
neurite outgrowth in differentiating neurons (68-71).  In this pathway, uPAR binds 
the inactive proform of urokinase plasminogen activator (pro-uPA), allowing it to 
be cleaved by cathepsins and become activated. The activated uPA proteinase 
then cleaves inactive plasminogen to form enzymatically active plasmin, which in 
turn cleaves inactive pro-MMPs to form active MMPs. This cascade has been 
implicated in neurite outgrowth and more generally in cell differentiation, tissue 
remodeling, cell invasiveness, and wound healing (reviewed in (72) and (73)).  It 
has also been suggested that uPAR is an immediate-early gene product of NGF 
whose function may be required for induction of secondary response genes 
important for differentiation, such as Mmp3 (69, 74).  In other cell types, uPAR 
has been reported to activate a variety of intracellular signaling pathways, 
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including JAK1/signal transducer and activator of transcription (STAT) 1 (75), 
MEK/ERK (76), the Src family kinase hck (77), and protein kinase Cε (78) 
pathways, as well as increase levels of signaling molecules including 
diacylglycerol (79, 80), cAMP (81), calcium released from internal stores (82), 
and inositol phosphate turnover (83).  uPAR has also been reported to form 
stable complexes with integrins that alter the adhesive properties of cells (84) 
(85).  Expression of SH2B1β with a mutant NLS does not promote the NGF-
induced expression of these genes, possibly explaining the lack of enhancement 
in NGF-induced neuronal differentiation seen for PC12 cells expressing SH2B1β 


















PC12 Cells: Cell Culture Model of Neuronal Differentiation 
 
The PC12 cell line has been commonly used as a model system to 
investigate the mechanisms of NGF-mediated neuronal differentiation and NGF 
signal transduction (86).  PC12 cells are derived from a solid rat 
pheochromocytoma tumor and, when treated with NGF, differentiate into a 
neuronal type cell with properties similar to those of sympathetic neurons (87).  
When PC12 cells are treated with NGF, they stop proliferating and initiate a 
differentiation process in which they exhibit cellular hypertrophy, produce neurite 
outgrowths, express neuronal-specific markers, and become electrically excitable 
(86, 87).  Differentiated sympathetic-like PC12 neuronal cells are able to form 
synapses with primary neurons (88), supporting the biological relevance of this in 
vitro cell line. 
 The PC12 cell model system has been used to elucidate the molecular 
pathways regulating the transformation to a mature neuron.  Upon NGF binding 
to TrkA, a series of post-translational protein modifications and differential gene 
expression leads to the biochemical and morphological cellular changes that 
contribute to the differentiated neuronal state.  NGF stimulation activates multiple 
signaling pathways including PI3K/Akt, PLC-γ, Ras/Raf/MEK/ERKs 1 and 2, Jun 
N-terminal kinase (JNK), p38, and atypical protein kinase Cs (89, 90).  Epidermal 
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growth factor (EGF), while promoting the opposite biological response of 
proliferation compared to differentiation, promotes the activation of some of the 
same signaling pathways in PC12 cells as NGF (91).  Whereas NGF-activated 
TrkA ceases cell division and promotes a differentiation protocol, activated EGF 
receptor (EGFR) promotes cellular proliferation (92).  Research into how 
activation of the same molecular pathways can lead to different biological 
responses has revealed that the duration of ERK activation is a primary factor 
responsible for the different responses.  A transient or brief activation of ERKs by 
EGF promotes mitogenesis while a more sustained activation in response to 
NGF promotes neurogenesis (93-96).  It has since been shown that ERK 
activation is required for NGF-induced PC12 cell neuronal differentiation (97, 98).  
It appears that the difference in the duration of ERK activation in response to 
NGF and EGF is due to differential recruitment of adaptor proteins to the active 
receptors.  Activated TrkA, but not EGFR, recruits a complex of proteins 
including the adaptor protein FRS2, Crk, C3G, Rap1 and B-Raf, which results in 
sustained ERK 1/2 activation (99, 100).  These works highlight the importance of 
understanding the roles of adaptor proteins in mediating the cellular responses to 
activated TrkA. 
 A schematic summarizing the functions of SH2B1β in response to NGF is 









FIG. 1.2. Schematic of SH2B1β function in response to NGF in PC12 cells.  
SH2B1β localizes at the plasma membrane and cytosol and cycles in and out of 
the nucleus.  SH2B1β acts to enhance NGF-induced gene expression and 
neurite outgrowth.  It is hypothesized that SH2B1β acts to form a transcription-
activating complex in the nucleus or promotes gene transcription by shuttling a 
repressor transcription factor out of the nucleus or a signaling molecule into the 






Human SH2B1 mutations are associated with maladaptive behaviors and 
obesity 
Abstract 
Src homology 2 B adapter protein 1 (SH2B1) modulates signaling by a variety of 
ligands that bind to receptor tyrosine kinases or JAK-associated cytokine 
receptors, including leptin, insulin, growth hormone (GH), and nerve growth 
factor (NGF).  Targeted deletion of Sh2b1 in mice results in increased food 
intake, obesity, and insulin resistance, with an intermediate phenotype seen in 
heterozygous null mice on a high-fat diet.  We identified SH2B1 loss-of-function 
mutations in a large cohort of patients with severe early-onset obesity.  Mutation 
carriers exhibited hyperphagia, childhood-onset obesity, disproportionate insulin 
resistance, and reduced final height as adults.  Unexpectedly, mutation carriers 
exhibited a spectrum of behavioral abnormalities that were not reported in 
controls, including social isolation and aggression.  We conclude that SH2B1 
plays a critical role in the control of human food intake and body weight and is 









 Leptin is a 16-kDa circulating hormone that regulates energy homeostasis 
via hypothalamic neurons expressing the leptin receptor (LEPR) (101).  
Congenital deficiency of leptin and its receptor results in severe obesity in 
rodents and humans, implicating leptin-mediated signaling in the regulation of 
food intake, energy expenditure, carbohydrate metabolism, and neuroendocrine 
function (10, 102).  Diet-induced obesity in rodents, and common forms of 
obesity in humans, are characterized by resistance to endogenous and 
exogenous leptin (103).  Dissecting the intracellular signaling pathways and 
hypothalamic neural circuitry by which leptin exerts its effects is critical for the 
identification of potential therapeutic targets for obesity (104).   
 Leptin mediates effects on energy balance by binding to the long form of 
LEPR (LEPRb) and activating LEPRb-associated JAK2 (105).  JAK2 
phosphorylates multiple tyrosines in LEPRb (Tyr985/1107/1138), enabling 
recruitment of downstream effectors.  JAK2 also autophosphorylates on Tyr813, 
allowing the binding of Src homology 2 (SH2) B adapter protein 1 (SH2B1), 
which enhances JAK2 activation and helps recruit insulin receptor substrate 
(IRS)1 and IRS2 to the LEPRb/JAK2 complex (18, 40).  This facilitates JAK2-
mediated tyrosine phosphorylation of IRS1/2 and subsequent activation of the 
PI3K pathway.   
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 SH2B1 is a key endogenous positive regulator of leptin sensitivity; targeted 
deletion in mice results in impaired leptin signaling and severe obesity (18).  
Sh2b1-null mice are also insulin resistant and exhibit impaired insulin signaling 
(51).  Multiple isoforms of SH2B1 are expressed in the brain; however, neuron-
specific restoration of recombinant Sh2b1β alone is sufficient to reverse the 
obesity observed in Sh2b1 knockout mice (54), which suggests that centrally 
expressed SH2B1β is critical to energy homeostasis.   
 To investigate the importance of SH2B1 in human energy homeostasis and 
insulin signaling, we sought to identify mutations in the SH2B1 gene in a group of 
severely obese patients.  We identified 300 patients with severe early-onset 
obesity from the Genetics of Obesity Study (GOOS) cohort (106) with a 
disproportionate degree of insulin resistance for their obesity, as defined by the 
presence of acanthosis nigricans, development of type 2 diabetes in early 
adolescence, and/or markedly elevated plasma insulin (top decile for age, gender, 
and BMI).  Mutations in the genes causing the known monogenic obesity 
syndromes had been excluded in these patients, as had deletions at 16p11.2 by 











Results and Discussion 
 We identified 5 probands of mixed European descent with heterozygous 
mutations in SH2B1 (FIG. 2.1): a frameshift mutation, F344LfsX20, which leads 
to a truncated protein product, and 3 missense mutations, P90H (2 patients), 
T175N, and P322S; all were absent from 500 control subjects (P < 0.001).  
Probands were apparently unrelated over 3 generations, as assessed by medical 
history.   
 All mutations were inherited from overweight/obese parents, and carriers 
were hyperphagic and had reduced final height as adults (Table 2.1).  Mutation 
carriers were hyperinsulinemic (fasting plasma insulin >60 pmol/l) and 
euglycemic; liver function tests and lipid profiles were within the normal range 
(data not shown).  Unexpectedly, we found that mutation carriers were reported 
to have delayed speech and language development and aggressive behavior by 
healthcare professionals and by family members (Table 2.1).  However, these 
individuals did not consent to further behavioral testing, so the precise nature and 
severity of these phenotypes could not be determined.  None of the controls were 
reported to have behavioral abnormalities by healthcare professionals. 
 We next sought to assess the molecular and cellular basis for the 
phenotypes associated with these human mutations.  SH2B1 is a member of a 













FIG. 2.1. Identification of SH2B1 mutations.  Human SH2B1 protein 
(NP_001139268). P, proline-rich region; DD, dimerization domain; NLS, nuclear 
localization sequence; NES, nuclear export sequence; PH, pleckstrin homology 
domain. SH2B1 mutations are shown, with nucleotide changes marked on the 
chromatograms (arrows). N, normal allele; M, mutated allele. 
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Table 2.1.  Phenotypic characteristics of SH2B1 mutation carriers. 
Probands were identified by genetic screening; other individuals are family 
members of probands as indicated. Data were only included where reports from 
healthcare professionals and family members were available. –, data missing (in 
some cases, family members were deceased or contact information was not 
available); N, normal allele; M, mutant allele. 
  





proband P90H 27 45 M NM Social isolation, aggression 




mother T175N 31 30 F NM Speech and language delay 
father T175N 30 29 M NN Nil 
sister T175N 7 21 (2.2) F NM Speech and language delay 
proband P322S 14 32 (2.9) M NM Social isolation, aggression 
mother P322S 54 27 F NM Nil 
father P322S 55 22 M NN Nil 
brother P322S 18 32 M NM Social isolation 
proband F344LfsX20 13 37 (3.5) F NM Social isolation, aggression 
mother F344LfsX20 48 48 F NM Social isolation 
father F344LfsX20 55 26 M NN Nil 
sister F344LfsX20 21 - F NN Nil 
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PSM), SH2B2 (also known as APS), and SH2B3 (also known as Lnk) — that 
bind to activated receptor tyrosine kinases, including insulin receptor and TrkA, 
the receptor for nerve growth factor (NGF) (39).  SH2B1 can also bind to 
activated JAK2 (108), a cytokine receptor–associated tyrosine kinase that is 
activated after binding of cytokine receptor ligands, such as leptin and growth 
hormone (GH).  SH2B1 has an amino-terminal dimerization domain, nuclear 
localization and export sequences, a central pleckstrin homology domain, and a 
carboxy-terminal SH2 domain (FIG. 2.1).   
 The SH2B1 transcript undergoes alternative splicing at the 3′ end, giving 
rise to four protein products (SH2B1α, SH2B1β, SH2B1γ, and SH2B1δ; ref. (28)) 
that share their amino termini, nuclear localization sequence, nuclear export 
sequence, pleckstrin homology domain, and SH2 domain, but differ at their 
carboxyl termini.  We investigated expression of the four SH2B1 isoforms in 
human tissues by RT-PCR (FIG. 2.2).  As the beta isoform is the predominant 
form in the hypothalamus, we introduced the mutations into SH2B1β and 
examined their effect on SH2B1β expression, subcellular localization, and ability 
to enhance NGF-induced neuronal differentiation, cycling through the nucleus, 
GH-induced macrophage motility, JAK2 activation, leptin signaling, and insulin 
signaling.  
 Previous studies implicated SH2B1 in neuronal differentiation induced by 
NGF or by glial cell line–derived neurotrophic factor (30, 35, 109).  To test the 
mutations’ effect on the ability of SH2B1β to enhance neuronal differentiation, we 





FIG. 2.2.  Expression profile of SH2B1 isoforms.  Expression of the 4 SH2B1 
isoforms (α, β, γ, and δ), studied by qualitative RT-PCR in a panel of human 
tissues. 
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tagged WT or mutant SH2B1β in PC12 cells, treated the cells with NGF to induce 
neuronal differentiation, and determined the percentage of GFP+ cells that were 
differentiated (neurite outgrowths >2 times the length of the cell body).  The 
truncation mutation failed to enhance NGF-induced neuronal differentiation, and 
the P90H, A175N, and P322S mutations significantly impaired the ability of 
SH2B1β to enhance neuronal differentiation compared with WT (FIG. 2.3).  
 Nuclear shuttling of SH2B1β appears to be required for its stimulatory effect 
on neuronal differentiation (62).  To test whether the mutations impair the ability 
of SH2B1β to translocate to the nucleus, we treated 293T cells expressing GFP-
tagged forms of SH2B1β with an inhibitor of nuclear export, leptomycin B, for 8 
hours.  While confocal microscopy revealed that approximately 95% of the cells 
expressing GFP-tagged WT SH2B1β showed a nuclear/cytoplasmic GFP 
fluorescence ratio of ≥ 1, cycling of the mutants into the nucleus was significantly 
impaired (FIG. 2.4).  
 SH2B1 has been implicated in GH regulation of the actin cytoskeleton (45).  
We therefore examined the ability of WT and mutant forms of SH2B1β to 
enhance GH-induced motility of cultured RAW264.7 macrophages.  In contrast to 
GFP-tagged WT SH2B1β, which stimulated both basal and GH-induced motility, 
the point mutants inhibited GH-induced motility (FIG. 2.5). 
 SH2B1β mutants P90H, A175N, and P322S were expressed at the 
appropriate size and intensities and retained their ability to activate JAK2 (FIG. 
2.6).  In contrast, the F344LfsX20 mutant exhibited significantly reduced  
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FIG. 2.3. SH2B1β with human mutations do not enhance NGF-induced 
PC12 cell differentiation to the same extent as WT.  PC12 cells transiently 
expressing GFP-tagged WT or mutant SH2B1β were treated with NGF to induce 
differentiation. Percent differentiated values were normalized against WT at day 
1 of differentiation (means ± SEM). All mutants impaired the rate of NGF-
induced neuronal differentiation compared with WT. *P < 0.0001, 1-way ANOVA 















































FIG. 2.4. All SH2B1β mutant proteins exhibited an impaired ability to 
accumulate in the nucleus.  (A) 293T cells transiently expressing GFP-tagged 
WT or mutant SH2B1β were treated with or without leptomycin B (LMB) (20mM) 
for 8 h and imaged using fluorescent confocal microscopy. Scale bars: 10 µm.  
(B) The percentage of GFP-positive cells (76-150 cells/condition/assay) that 
exhibited nuclear fluorescence signal intensity greater than or equal to the 
cytoplasmic fluorescence signal intensity was determined. Means ± SEM are 
shown where n = 5, 4 and 3 independent experiments for WT, point mutants 
and F344LfsX20, respectively. (*) p<0.05 compared to WT using an unpaired, 
two-tailed Student’s t test. p = 0.0128, 0.0004, 0.0001 and 0.0062 for P90H, 
P322S, A175N and F344LfsX20, respectively. (#) All experiments were 
performed using rat SH2B1β where Thr175 is Ala175 and therefore the T175N 





FIG. 2.5. SH2B1β with human mutations inhibit GH-induced cell migration.  
RAW264.7 macrophages transiently expressing GFP-tagged WT or mutant 
SH2B1β were added to the upper chamber, and GH (500 ng/ml) to the lower 
chamber, of a Transwell plate. Average values for migrated cells were 
normalized to unstimulated control values (means ± SEM). All SH2B1β mutants 
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FIG. 2.6. SH2B1β P90H, P322S and A175N express at the appropriate size 
and to a similar extent as WT.  They also exhibit similar enhancement of 
JAK2 phosphorylation.  Proteins in lysates from 293T cells transiently 
expressing Flag-JAK2 and GFP-SH2B1β WT, P90H, P322S, or A175N (as 
indicated) were separated by SDS-PAGE and immunoblotted with α-GFP (top 
panel), α-JAK2pY1007 (middle panel), or α-JAK2 (bottom panel). 
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expression and was unable to activate JAK2 (FIG. 2.7), presumably due to the 
fact that it lacks the SH2 domain previously shown to be required for JAK2 
activation (22).  
 SH2B1β F344LfsX20 was also present at lower levels in the plasma 
membrane relative to the cytoplasm in both 293T and PC12 cells and was found 
in aggregates in the cytoplasm (FIG. 2.8 and FIG. 2.9).  SH2B1β P90H, A175N, 
and P322S exhibited a steady-state subcellular distribution similar to that of WT 
SH2B1β in 293T and PC12 cells (FIG. 2.8 and FIG. 2.9).   
 We assessed the ability of the SH2B1β mutants to enhance leptin signaling 
by examining their ability to stimulate leptin-dependent tyrosyl phosphorylation of 
IRS2.  Consistent with the findings on JAK2 activation, the SH2B1β point 
mutants were as effective as WT SH2B1β in stimulating leptin-dependent 
tyrosine phosphorylation of IRS2 (FIG. 2.10); similar results were seen for 
insulin-stimulated tyrosine phosphorylation of IRS2 (FIG. 2.11).  As these latter 
assays rely on the overexpression of both SH2B1β and IRS2, it is possible that 
any subtle effects of the SH2B1 mutants were masked. 
 We also postulated that some of these heterozygous mutations may affect 
the ability of SH2B1 to dimerize.  GFP-tagged WT SH2B1β co-
immunoprecipitated with Flag-tagged WT SH2B1β, while the mutant 3AD/2FA (in 
which the phenylalanine zipper that is required for dimerization is mutated) 
exhibited greatly diminished coimmunoprecipitation (FIG. 2.12).  Binding of the 
GFP-tagged P90H and A175N mutants to Flag-tagged WT SH2B1β was similar 
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FIG. 2.7. SH2B1β truncation mutant F344LfsX20 expresses at the 
appropriate size but at a much lower level than WT. It does not enhance 
JAK2 phosphorylation.  Proteins in lysates from 293T cells transiently 
expressing Flag-JAK2 (0.5 µg cDNA) and GFP-SH2B1β WT or F344LfsX20 (at 
the indicated µg cDNA amount) were separated by SDS-PAGE and 
immunoblotted with α-GFP (top panel), α-JAK2pY1007 (middle panel), or α-
JAK2 (bottom panel).  The migrations of molecular weight standards are 





FIG. 2.8. Subcellular distribution of SH2B1β WT and mutant proteins in 
293T cells. Live 293T cells transiently expressing GFP-tagged WT, P90H, 
A175N, P322S, or F344LfsX20 SH2B1β were stained with the plasma 
membrane marker wheat germ agglutinin Alexa Fluor 594 (red) and imaged 
using confocal fluorescence microscopy. Shown are GFP fluorescence alone 
(green; top) and overlay of GFP and plasma membrane marker (bottom). Scale 
bars: 10 µm. Below, green and red signal intensity along the yellow arrows was 
determined using MetaVue Linescan. Arrows (red signal intensity peak) indicate 
position of the plasma membrane on the linescan. Horizontal lines on the 
linescan graphs denote the plasma membrane and cytoplasm values used to 
determine the plasma membrane/cytoplasm green signal intensity ratios (means 
± SEM). The SH2B1β truncation mutant localized to the PM to a lesser extent 
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FIG. 2.9. Subcellular distribution of SH2B1β WT and mutant proteins in 
PC12 cells. Live PC12 cells transiently expressing GFP-tagged WT, P90H, 
A175N, P322S, or F344LfsX20 SH2B1β were imaged using confocal 
fluorescence microscopy. Scale bars: 10 µm.  Green signal intensity along the 
yellow arrows was determined using MetaVue Linescan. Arrows indicate 
position of the plasma membrane on the linescan. Horizontal lines on the 
linescan graphs denote the plasma membrane and cytoplasm values used to 
determine the plasma membrane/cytoplasm green signal intensity ratios (means 
± SEM). The SH2B1β truncation mutant localized to the PM to a lesser extent 





FIG. 2.10. SH2B1β mutants enhance leptin-induced tyrosyl 
phosphorylation of IRS2 to the same extent as SH2B1β WT.  Flag-IRS2 and 
GFP-SH2B1β WT, P90H, P322S or A175N were transiently co-expressed (as 
indicated) in HEK293 cells stably expressing leptin receptor and treated with 
leptin (100 ng/ml) for 10 minutes.  Flag-IRS2 was immunoprecipitated with α-
Flag and immunoblotted with α-phospho-tyrosine 4G10 (top panel) or α-Flag 





FIG. 2.11. SH2B1β mutants enhance insulin-induced tyrosyl 
phosphorylation of IRS2 to the same extent as SH2B1β WT.   Flag-IRS2 and 
GFP-SH2B1β WT, P90H, P322S or A175N were transiently co-expressed (as 
indicated) in 293T cells and treated with 2.5 nM insulin for 30 minutes.  Flag-
IRS2 was immunoprecipitated with α-Flag and immunoblotted with α-phospho-
tyrosine 4G10 (top panel) or α-Flag (middle panel).  Total lysates were blotted 
with α-myc (bottom panel). 
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FIG. 2.12. Dimerization of SH2B1β with human mutations.  Flag-tagged 
SH2B1β was immunoprecipitated from HEK293 cells coexpressing Flag- tagged 
WT SH2B1β and GFP-tagged SH2B1β mutants (including the dimerization 
mutant 3AD/2FA). Immunoprecipitated proteins and proteins in cell lysates were 
immunoblotted using anti-Flag and anti-GFP antibodies. Binding of the P90H 
and A175N mutants was similar to that seen with WT; however, the P322S 
mutation enhanced dimerization. Note that for the A175N mutant, all 
experiments were performed using rat SH2B1β (NP_001041645), in which 
Thr175 is Ala175. 
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dimerization. 
 We have demonstrated that loss-of-function mutations in SH2B1 were 
associated with severe early-onset obesity, insulin resistance, and reduced final 
height.  All the mutations were associated with loss of function in assays of 
GH/NGF-mediated signaling.  Intriguingly, apart from the frameshift mutation, the 
other mutants did not impair leptin signaling.  Although this discordance may 
reflect the differing sensitivities of the assays used, it is plausible that some of the 
effects of SH2B1 on energy homeostasis may be mediated by leptin-independent 
pathways. 
 Unexpectedly, we observed that mutations were associated with a range of 
behavioral abnormalities, including a tendency for social isolation and high levels 
of aggression, as reported by healthcare professionals and family members.  We 
recognize that the absence of formal psychiatric testing and disease 
classification in these individuals and in the controls is a limitation of our study.  
However, we note that these phenotypes were not seen in association with the 
other genetic obesity syndromes we have characterized to date (106, 107), 
although the socioeconomic status of mutation carriers was comparable.  As we 
observed impaired NGF-induced neuronal differentiation in vitro, a similar 
response to other ligands, such as centrally expressed neurotrophins, could 
contribute to these features (14).  The maladaptive behaviors reported in 
mutation carriers compared with controls were not reported in previous studies in 








 SH2B1 mutation analysis.  All 300 patients from the GOOS study that fit 
the criteria for obesity and severe insulin resistance were screened for mutations 
in the SH2B1 gene.  An a priori power calculation was not conducted; given the 
rarity of these phenotypes, all eligible patients available to us were studied.  
Primers were designed to cover the coding sequence (NM_015503) and splice 
junctions of SH2B1.  Mutation screening was undertaken by PCR, followed by 
direct sequencing using BigDye terminator chemistry (Applied Biosystems) and 
analysis on an ABI 3730 automated sequencer (Applied Biosystems).  500 
controls were also sequenced using the same methods. 
 SH2B1 gene expression in human tissues.  A human tissue cDNA library 
was prepared using 1 µl RNA (Clontech), which was reverse transcribed to cDNA 
using a RetroScript kit (Ambion).  1 µl cDNA was used as a template in an RT-
PCR reaction (forward primer, 5′-CAGCTATGTCCCATCCTCCCAGCGA-3′; 
reverse primer, 5′-CAGGCTGTGGGGGATCTGTCCATGAAG-3′).  The four 
SH2B1 isoforms were amplified simultaneously, generating four PCR products of 
distinct size (SH2B1α, 102 bp; SH2B1β, 201 bp; SH2B1γ, 254 bp; SH2B1δ, 154 
bp). 
 Expression plasmids.  The PC12 and RAW264.7 cells used to 
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characterize the functional impact of the mutants are derived from rat and mouse 
respectively, so we used a cDNA encoding a rodent (rat) SH2B1β.  Mutant GFP- 
SH2B1β cDNA was created using QuikChange Site-Directed Mutagenesis Kit 
(Stratagene).  Mouse IRS2 was cloned into pcDNA(3.1-) vector (Flag-tag at N-
terminus). 
 Cell culture and transfection.  Q293A cells stably expressing the long 
form of the mouse leptin receptor (293LRb)(110), HEK 293 cells, and 293T cells 
were transiently transfected using the polyethylenimine (PEI) method.  PC12 
cells were cultured in RPMI 1640 (ATCC) containing 10% horse serum 
(Invitrogen) and 5% fetal bovine serum (FBS) (Atlanta Biologicals) on collagen-
coated dishes and transfected as described previously (35).  RAW264.7 cells (J. 
Swanson, University of Michigan) were cultured in DMEM (Invitrogen) 
supplemented with 8% heat inactivated FBS (Atlanta Biologicals), 1 mM L-
glutamine and 1 mM antibiotic-antimycotic (Invitrogen) at 37°C in 5% CO2.  
RAW264.7 cells were transiently transfected using Amaxa nucleofector (Lonza) 
using solution V and setting D32. 
 Neuronal differentiation of PC12 cells.  Transfected PC12 cells were 
plated on collagen-coated 60-mm dishes.  24 hours post transfection, 25 or 50 
ng/ml NGF (BD Bioscience) was added to RPMI 1640 containing 5% horse 
serum, 1% FBS to induce PC12 cell differentiation.  NGF-containing 
differentiation medium was refreshed two days later.  The cells were visualized 
by fluorescence microscopy (Nikon Eclipse TE200).  The percent of GFP+ cells 
that were differentiated (neurite outgrowths >2 times the length of the cell body) 
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was determined. 
 Cell Imaging.  Transfected 293T cells plated on 35-mm, poly-d-lysine-
coated glass-bottom culture dishes (MatTek Corp., Ashland, MA) were incubated 
for 8 hours in growth medium supplemented with 20 nM leptomycin B (Sigma) to 
inhibit Crm1-dependent nuclear export.  GFP+ cells were visualized with an 
Olympus FluoView 500 laser scanning confocal microscope using a 60x water-
immersion objective and FluoView version 5.0 software.  Linescan profiles were 
obtained and analyzed using MetaVue Software (Universal Imaging, Sunnyvale, 
CA). 
 GH-induced migration of RAW264.7 macrophages.  RAW264.7 cells 
transiently expressing SH2B1β WT or mutant were incubated in growth medium 
for 24h, then in serum-free medium (1% BSA) overnight.  Transfected cells 
suspended in serum-free medium were added to the upper chamber of a 
Transwell (Costar) unit with 5-µm pore size; the lower chamber contained serum-
free medium with 500 ng/ml recombinant human GH (gift of Eli Lilly & Co.).  
Transwell units were incubated at 37°C for 18 h, fixed in methanol and air-dried. 
Cells in the upper chamber were removed with a cotton swab.  Filter membranes 
were stained with hematoxylin and eosin (H&E) (1:10 dilution) for 1 hour and 
then washed with ddH2O.  Cells that had migrated were counted (≥3 
independent fields per condition) under a light microscope. 
 SH2B1 dimerization.  HEK293 cells were transiently transfected with Flag- 
and GFP-tagged SH2B1β constructs.  36h post-transfection, cells were washed 
with PBS, harvested in NP-40 lysis buffer and clarified by centrifugation.  Lysate 
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(3 mg protein) was pre-cleared by incubation with Protein A agarose (Sigma) at 
4°C for 30 min before incubation with anti-FLAG M2 affinity gel (Sigma) at 4°C 
overnight.  Immunoprecipitates were washed, resuspended in sample buffer and 
filtered through a Spin-X filter to remove the resin.  NuPAGE reducing agent (1X; 
Invitrogen) was added to the eluted samples, which were subjected to 
electrophoresis and immunoblot analysis. 
 Statistics.  To test for statistically significant differences in values from the 
neuronal differentiation assay (n=4-8 experiments, 60-120 
cells/condition/experiment), a one‐way ANOVA with a Dunnett’s multiple 
comparison post-test was applied.  For the values from each day of the assay 
(days 1-4), the ANOVA yielded p-values < 0.0001 and the Dunnett’s post-test 
showed significant differences between GFP-SH2B1β WT-expressing cells and 
every other condition (alpha = 0.05).  For nuclear accumulation of GFP-SH2B1β 
(n=3-5 experiments, 76-150 cells/condition/experiment) and subcellular 
localization (n=16-26), statistical significance was determined using an unpaired, 
two-tailed Student’s t-test.  For the motility assay (n=4), a paired, one‐tailed 
Student’s t-test was used.  2-sided Fisher’s exact test was used to compare 
prevalence of mutations in cases versus controls.  A P-value less than 0.05 was 
considered significant. 
 Study subjects.  The Genetics of Obesity Study (GOOS) cohort consists of 
4300 probands with severe obesity (Body Mass Index Standard Deviation Score 
(BMI SDS) >3) before 10 years of age.  BMI SDS values were calculated using 
UK reference data (111).  We identified three hundred patients who also 
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exhibited disproportionate insulin resistance as defined by the presence of 
acanthosis nigricans, the development of type 2 diabetes in early adolescence 
and/or markedly elevated plasma insulin levels (top decile for age, gender and 
body mass index).  The mean (±SD) BMI SDS for this group of 300 chosen for 
study was 4.3 ± 1.4.  In adults, overweight was defined as BMI 25-29.9 kg/m2, 
obesity as BMI > 30 kg/m2 according to WHO criteria.  In children (<18yrs), we 
used definitions proposed by the International Obesity Task Force: overweight 





















Effects of human mutations on cellular actions of SH2B1 alpha 
Abstract 
SH2B1 modulates signaling by a variety of ligands that bind to receptor tyrosine 
kinases or JAK-associated cytokine receptors, including leptin, insulin, growth 
hormone (GH), and nerve growth factor (NGF).  Targeted deletion of Sh2b1 in 
mice results in increased food intake, obesity, and insulin resistance, with an 
intermediate phenotype seen in heterozygous null mice on a high-fat diet.  
SH2B1 is expressed as four different isoforms alpha, beta, gamma, and delta.  
Previously, SH2B1 loss-of-function mutations have been identified in a large 
cohort of patients with severe early-onset obesity and the effects of which on 
cellular actions of SH2B1β were investigated.  Here, we identify additional 
mutations present in SH2B1 from obese patients with disproportionate insulin 
resistance, including three mutations exclusive to the alpha isoform.  We 
investigated the effects of these mutations on cellular actions of SH2B1α.  We 
did not see a difference between SH2B1α WT or mutant to enhance JAK2 
activation, promote insulin-mediated IRS2 phosphorylation, or localize at the 
plasma membrane.  In contrast to SH2B1β, SH2B1α does not enhance NGF-
induced neurite outgrowth or uPAR expression and does not cycle through the 
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nucleus.  We show that it is mostly the unique C-terminal tail of SH2B1α that 



























Recently, SH2B1 has been identified as an obesity gene.  Humans with 
point mutations found in SH2B1 exhibit severe early-onset obesity, extreme 
insulin resistance, and maladaptive behavior (112).  The effects of these 
mutations on the cellular actions of SH2B1 were investigated with the beta 
isoform of SH2B1 (112).  SH2B1β with human mutations showed impaired 
enhancement of NGF-induced neuronal differentiation, nuclear accumulation, 
and growth hormone-induced macrophage motility.  The hyperphagia and 
maladaptive behavior seen in these patients hint at a possible role for SH2B1 in 
neuronal development.  This is supported by the effects of neuronal SH2B1 in 
mice with a whole-body knockout of Sh2b1.  Sh2b1-/- mice are obese and insulin 
resistant (18), yet when transgenic mice are created using a neuronal-specific 
enolase promoter to express SH2B1β only neurons, the metabolic disorder 
phenotype is ameliorated (54). In addition to mutations P90H, T175N, P322S, 
and F344LfsX20 that were first reported (112), more mutations have been 
identified in SH2B1, including ones specific to the alpha isoform of SH2B1. 
The adaptor protein SH2B1 is expressed as four different isoforms (alpha, 
beta, gamma and delta) that arise due to alternative splicing (28, 29).  The 
SH2B1 isoforms are identical in their sequence until the variable splice site 
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produces unique C-terminal tails for each.  While the beta isoform has been well 
characterized, there has not been much investigation into the alpha isoform.  
The alpha isoform has been seen to behave similarly to SH2B1β in 
promoting mitogenesis and cell survival in NIH 3T3 fibroblasts (28), and insulin 
receptor kinase activity in 3T3-L1 adipocytes (49).  SH2B1β and γ have been 
reported to enhance NGF-induced PC12 cell neuronal differentiation (30, 31), in 
part by promoting the expression of a sub-set of NGF-induced genes required for 
differentiation (67).  Nuclear-cytoplasmic shuttling of SH2B1β appears to be 
required for this enhancement of NGF-induced neuronal differentiation (62).  
Human mutations identified in SH2B1 impair the ability of SH2B1β to enhance 
NGF-induced neuronal differentiation (112).   
An N-terminal nuclear localization signal (NLS) and nuclear export 
sequence (NES) allow for the nuclear shuttling of SH2B1β.  The NLS and NES 
motifs present in SH2B1β are also present in SH2B1α, suggesting SH2B1α may 
also cycle through the nucleus.  While SH2B1β is ubiquitously expressed, 
SH2B1α appears to only be expressed in brain tissues (112).  Thus, it is 
important to gain a better understanding of the cellular functions of SH2B1α, 
particularly in neuronal differentiation, and how these are affected by the human 
mutations.   
 In this report we characterize the effects of SH2B1α WT or with a human 
mutation incorporated on NGF-induced neuronal differentiation and gene 
expression, JAK2 autophosphorylation, insulin-stimulated IRS2 phosphorylation, 





Methods and Materials 
 
Antibodies and reagents.  αFLAG (M2) (1:2000) was from Sigma.   
αJAK2 p1007/1008 (1:1000) was from Upstate Biotechnology Inc. (Lake Placid, 
NY).  αphospho-tyrosine 4G10 (1:1000) was from EMD Millipore Corporation 
(Billerica, MA).  IRDye800-conjugated anti-GFP, IRDye700 and IRDye800 
conjugated anti-mouse and anti-rabbit IgG (Rockland Immunochemicals, 
Gilbertsville, PA) were used at a dilution of 1:20,000.  NGF and rat-tail collagen I 
were purchased from BD Bioscience (San Diego, CA).   
Plasmids. Human SH2B1α (from S. Shoelson, Joslin Diabetes Center, 
Boston, MA) (NM_001145795.1) and rat SH2B1β (NM_001048180) were cloned 
into the pEGFP C1 vector (Clontech, Mountain View, CA) (described previously 
(62)).  Mutations were introduced using the QuickChange Mutagenesis kit 
(Stratagene).  All constructs were verified by sequencing. 
Cell Culture and Cell Lines.  The parental PC12 cells were obtained 
from American Type Culture Collection (ATCC) (Rockville, MD).  PC12 cells were 
plated on collagen-coated plates (0.1 mg/ml rat tail collagen in 0.02 N acetic 
acid) and grown at 37°C in 5% CO2 in normal growth medium containing RPMI 
1640 (ATCC), 10% heat-inactivated horse serum (Invitrogen), and 5% fetal 
bovine serum (Atlanta Biologicals).  PC12 cells were transfected using a Gene 
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Pulser Xcell Electroporator (400V, 500µF) in a 0.4 cm cuvette (Bio-Rad).  293T 
cells (from Dr. O. A. MacDougald, University of Michigan, Ann Arbor, MI) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 8% calf serum 
(Atlanta Biologicals) and transfected using calcium phosphate. 
Confocal Microscopy.  Cell imaging was performed using an Olympus 
FluoView 500 laser scanning confocal microscope and FluoView version 5.0 
software.  Transfected 293T cells were plated on poly-d-lysine coated glass 
bottom dishes (MatTek, Ashland, MA) and imaged while in Ringer’s buffer (10 
mM HEPES, 155 mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM 
NaH2PO4 and 10 mM glucose, pH 7.2).  Linescan profiles were obtained and 
analyzed using MetaVue Software (Universal Imaging, Sunnyvale, CA) and has 
been described previously (65). 
Differentiation of PC12 cells.  PC12 cells were grown on collagen-
coated 10-cm2 dishes then plated on collagen-coated 60-mm2 dishes after 
transfection. 24 h post transfection, 25 ng/ml NGF was added to RPMI 1640 
containing 5% horse serum, 1% FBS to induce PC12 cell differentiation.  NGF-
containing differentiation medium was refreshed two days later.  The cells were 
visualized by fluorescence microscopy (Nikon Eclipse TE200).  The percent of 
GFP+ cells that were differentiated (neurite outgrowths >2 times the length of the 
cell body) was determined.  
Cell lysis and immunoblotting.  Cells were solubilized in sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample lysis buffer (50 
mM Tris [pH 7.5], 1% SDS, 0.001% bromophenol blue, 10% glycerol, 0.1% Triton 
 50 
X-100, 150 mM NaCl, 2 mM EGTA) and proteins were separated by SDS-PAGE.  
Proteins in the gel were transferred to a nitrocellulose membrane and detected 
by immunoblotting with the indicated antibodies.  Blots were then incubated with 
infrared dye-conjugated secondary antibodies and visualized using the Odyssey 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). 
qPCR.  Total RNA was isolated using Stat60 (Tel-Test) and cDNA was 
generated using TaqMan Reverse Transcription kit (Applied Biosystems, 
Branchburg, NJ).  Gene expression was assessed using SYBR Green (Bio-Rad) 
and the Eppendorf Mastercycler ep (Hamburg, Germany).  All readings were 
normalized to the expression of glyceraldehyde-3- phosphate dehydrogenase 



















Additional human mutations identified in SH2B1.  The human 
mutations identified previously to affect the function of SH2B1β are also present 
in SH2B1α.  Since the publication of the initial report characterizing human 
mutations in SH2B1 (112), more mutations in SH2B1 from patients with early 
onset obesity and extreme insulin resistance have been identified.  Most 
mutations are common to all SH2B1 isoforms, including the previously reported 
P90H, T175N, P322S, F344LfsX20, and the novel G238C, R270W, A484T and 
T546A.  However, some mutations have been identified that are present in only 
the SH2B1 alpha (or delta) isoform; these include: A663V (which corresponds to 
a R680C in the delta isoform), V695M (which does not result in an altered amino 
acid sequence in the delta isoform), and A723V.  (FIG. 3.1) The effects of these 
mutations on SH2B1α cellular function are characterized in this report. 
SH2B1α enhances JAK2 autophosphorylation.  SH2B1β was originally 
identified as a binding partner for the receptor-associated tyrosine kinase JAK2 
(22).  Many cytokine and growth factor receptors utilize JAK2 to mediate their 
signal transduction, including the receptors growth hormone (GH) and leptin.  
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FIG. 3.1. Identification of human mutations in SH2B1α.  P, proline-rich 
region; DD, dimerization domain; NLS, nuclear localization sequence; NES, 
nuclear export sequence; PH, pleckstrin homology domain, SH2B1α unique C-
terminal tail in light blue. SH2B1α mutations are shown in boxes. 
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JAK2 tyrosine kinase signaling activity.  This requires an intact SH2 domain of 
SH2B1β to bind to phospho-tyrosine 813 of JAK2 (40, 113). 
To determine whether SH2B1α, like SH2B1β, activates JAK2, 293T cells 
were transiently transfected with Flag-tagged JAK2 with or without GFP-tagged 
SH2B1α WT.  JAK2 activity was assessed by blotting with α-pJAK2 Y1007/1008, 
which recognizes the active form of JAK2.  SH2B1α WT is able to enhance JAK2 
activity, similarly to what is seen when JAK2 is co-expressed with SH2B1β (FIG. 
3.2).  Next we tested whether human mutations identified in SH2B1 impaired the 
ability of SH2B1α to activate JAK2.  SH2B1α with human mutations P90H, 
T175N, G238C, R270W, P322S, A484T, T546A, A663V, V695M, and A723V all 
express at the expected size and intensity.  FIG. 3.2 shows that 10 of the 
mutants enhance JAK2 activity to the same extent as SH2B1α WT.  However, 
SH2B1α F344LfsX20 expressed at a much lower intensity than SH2B1α WT and 
was unable to promote the autophosphorylation of JAK2, consistent with what 
was seen with SH2B1β F344LfsX20 (see FIG. 2.7).   
SH2B1α F344LfsX20 and SH2B1β F344LfsX20 are expected to encode 
the same protein product since the mutation produces a truncated protein 
consisting of only the shared region of SH2B1 common to all four isoforms.  The 
SH2B1α F344LfsX20 truncated protein product does not contain the SH2 domain 
of SH2B1, which is responsible for binding to phospho-tyrosine residues and 
mediating tyrosine kinase signaling through SH2B1.  Thus, it was not surprising 






































































































FIG. 3.2. SH2B1α point mutants but not F344LfsX20 enhance JAK2 
activity.  Proteins in lysates from 293T cells transiently expressing Flag-JAK2 
and GFP-SH2B1α WT, F344LfsX20, P90H, P322S, T175N, G238C, R270W, 
P322S, A484T, T546A, A663V, V695M, or A723V (as indicated) were separated 
by SDS-PAGE and immunoblotted with α-JAK2pY1007 (top panel), α-Flag 
(middle panel), or α-GFP (bottom panel). 
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SH2B1α point mutants promote insulin-mediated IRS2 
phosphorylation.  SH2B1β has been shown previously to alter insulin signaling 
(49, 51).  Insulin signaling was dramatically impaired in muscle, liver, and 
adipose tissue when Sh2b1 was knocked out, whereas SH2B1β overexpression 
enhanced insulin receptor autophosphorylation and tyrosine phosphorylation of 
insulin receptor substrates (IRS) 1 and 2 (51).  To assess the effect of SH2B1α 
with human mutations on insulin signaling, 293T cells were transiently 
transfected with Flag-tagged IRS2 and either GFP-tagged SH2B1α WT or 
SH2B1α with a human mutation.  SH2B1α WT is able to enhance the insulin-
stimulated tyrosyl phosphorylation of IRS2, similar to SH2B1β (FIG. 3.3).  The 
SH2B1α point mutants P90H, T175N, G238C, R270W, and P322S enhance 
insulin-stimulated tyrosyl phosphorylation of IRS2 to the same extent as SH2B1α 
WT.  Consistent with what was seen from the JAK2 signaling assay, SH2B1α 
F344LfsX20 failed to promote the tyrosyl phosphorylation of IRS2 in response to 
insulin (FIG. 3.3).  It was not expected that SH2B1α F344LfsX20 would enhance 
insulin signaling because the SH2 domain of SH2B1 is required for SH2B1 to 
bind phospho-tyrosines in the active insulin receptor as well. 
SH2B1α does not enhance NGF-induced neuronal differentiation or 
uPAR expression. To assess whether SH2B1α, like SH2B1β, is able to 
enhance NGF-induced neuronal differentiation, PC12 cells were transiently 
transfected with GFP-SH2B1β or GFP-SH2B1α.  Overexpression of SH2B1β 
greatly enhanced NGF-induced PC12 cell neuronal differentiation over GFP- 
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FIG. 3.3. SH2B1α point mutants but not F344LfsX20 enhance insulin-
induced IRS2 tyrosyl phosphorylation.  GFP-tagged human SH2B1α mutants 
were expressed along with Flag-tagged IRS2 in HEK293 cells. Transfected cells 
were serum-starved for 16hrs and then treated with 100nM insulin for 5min. Cell 
lysates were subjected to immunoprecipitation with Flag-agarose beads and 
immunoblotting was carried out using the indicated antibodies. 
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expressing control cells as seen previously (112).  In contrast, overexpression of 
SH2B1α had no stimulatory effect (FIG. 3.4).   
NGF-induced expression of uPAR is required for neuronal differentiation 
(69) and has been seen to depend on SH2B1 for its full NGF-induced 
expression.  When SH2B1 expression is decreased using shRNA, NGF-induced 
expression of uPAR is decreased.  Conversely, NGF-induced expression of 
uPAR is increased when SH2B1β is overexpressed in PC12 cells (62, 67).  We 
therefore looked to see if SH2B1α enhanced NGF-induced expression of uPAR.  
In PC12 cells stably expressing GFP-SH2B1α and stimulated with NGF for 6 
hours, uPAR expression was not significantly higher than in control cells.  In 
contrast, PC12 cells transfected with SH2B1δ, which we have shown to enhance 
NGF-induced neuronal differentiation (described in chapter 4), promoted a large 
enhancement of NGF-induced uPAR expression (FIG. 3.5). 
SH2B1α does not cycle through the nucleus.  Previous work suggests 
that nuclear entry is critical for SH2B1 to promote NGF-induced differentiation 
and gene expression (62).  To assess whether SH2B1α is capable of shuttling 
through the nucleus as SH2B1β is, 293T cells were transiently transfected with 
GFP-SH2B1β or GFP-SH2B1α and incubated with the nuclear export inhibitor 
leptomycin B (LMB) for 13 hours.  Under steady-state conditions, SH2B1α and 
SH2B1β both appear localized at the plasma membrane (PM) and cytosol.  
However, in contrast to SH2B1β, which showed substantial nuclear accumulation 
with LMB treatment, SH2B1α failed to accumulate in the nucleus  
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FIG. 3.4. SH2B1α does not enhance NGF-induced PC12 neurite outgrowth.  
PC12 cells expressing GFP, GFP-SH2B1β, or GFP-SH2B1α were treated with 
NGF (25 ng/ml) to induce differentiation.  Neurites > 2X cell body length were 
counted as differentiated.  Means ± SEM, n = 3, * p,0.05. 
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FIG. 3.5. SH2B1α does not enhance NGF-induced uPAR expression.  PC12 
cells expressing GFP (-), GFP- SH2B1α or GFP-SH2B1δ were treated with NGF 
(25 ng/ml) to induce differentiation for 6h.  uPAR mRNA was analyzed by qPCR. 
Levels of uPAR mRNA were normalized to levels of GAPDH mRNA and then 
further normalized to levels of mRNA in control cells (GFP).  Representative 
experiment. 
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with LMB (FIG. 3.6).  This result suggests that SH2B1α does not constitutively 
shuttle through the nucleus as SH2B1β does, providing one possible explanation 
for why SH2B1α is unable to promote NGF-induced neuronal differentiation and 
gene expression. 
SH2B1α is localized at the PM to a lesser extent than SH2B1β.  
Because SH2B1α does not enter the nucleus as SH2B1β does, we wanted to 
determine whether SH2B1α localizes differently at other sub-cellular 
compartments compared to SH2B1β.  To assess this, 293T cells were transiently 
transfected with GFP-SH2B1β or GFP-SH2B1α WT and live cells were imaged 
by confocal microscopy.  Linescans using MetaVue software were used to 
measure the fluorescence signal intensities for GFP-SH2B1 emanating from the 
plasma membrane (PM) and cytosol.  While the PM:cytosol signal intensity ratio 
for SH2B1β is greater than 2, the PM:cytosol signal intensity ratio for SH2B1α 
WT is significantly less at ~1.5 (FIG. 3.7).  To determine if serum levels in the 
medium affect the PM:cytosol ratio of SH2B1, 293T cells were transiently 
transfected with GFP-SH2B1β or GFP-SH2B1α and incubated with 8% calf 
serum or without serum for 16 hours.  Live cells were imaged using confocal 
microscopy.  Serum increased the amount of SH2B1β at the PM (PM:cytosol 
signal intensity ratio >2 with serum compared to ~1.5 without).  In contrast, 
SH2B1α did not show a change in PM localization with serum (FIG. 3.8).  In the 
absence of serum, SH2B1α and SH2B1β have similar PM:cytosol ratios.  
However, serum increases the amount of SH2B1β at the PM but not the amount 
of SH2B1α.  Although SH2B1α is capable of mediating tyrosine kinase signaling  
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FIG. 3.6. SH2B1α exhibits impaired ability to translocate to the nucleus. 
Live 293T cells expressing rat GFP-SH2B1β or human GFP-SH2B1α ± LMB for 
























































































FIG. 3.7. Subcellular distribution of SH2B1α WT and mutant proteins. Live 
293T cells transiently expressing GFP-tagged SH2B1β WT, SH2B1α WT, or 
SH2B1α with a human mutation were stained with the plasma membrane 
marker wheat germ agglutinin Alexa Fluor 594 and imaged using confocal 
fluorescence microscopy. Green and red signal intensities were determined 
using MetaVue Linescan. The plasma membrane:cytoplasm signal intensity 
































FIG. 3.8. Subcellular distribution of SH2B1β and SH2B1α WT in response 
to serum.  Live 293T cells transiently expressing GFP-tagged SH2B1β WT or 
SH2B1α WT were stained with the plasma membrane marker wheat germ 
agglutinin Alexa Fluor 594 and imaged using confocal fluorescence microscopy.  
Cells without serum were deprived for ~16 h before imaging.  Green and red 
signal intensities were determined using MetaVue Linescan.  The plasma 
membrane:cytoplasm signal intensity ratios (means ± SEM) are shown.  *P < 
0.001. 
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(such as for the insulin receptor (49)), these data suggest that SH2B1β may be 
more active at the PM in response to cytokine and growth factor signaling.      
The C-terminal of tail SH2B1α inhibits the ability of SH2B1 to 
promote NGF-induced neuronal differentiation.  Because the sole differing 
region between the isoforms of SH2B1 is their unique C-termini, we asked 
whether the unique C-terminal region of SH2B1α is responsible for the inability of 
SH2B1α to enhance NGF-induced neuronal differentiation.  To test this 
hypothesis, a truncated form of SH2B1 was created where a stop codon was 
inserted before the variant splice site in order to produce a SH2B1 protein 
product (SH2B1 1-620) without the variable C-terminal region.  This form of 
SH2B1 is isoform neutral.  PC12 cells were transiently transfected with GFP, 
GFP-SH2B1β, or GFP-SH2B1 1-620 and treated with NGF to induce neuronal 
differentiation.  In contrast to SH2B1α, SH2B1 1-620 enhances NGF-induced 
neuronal differentiation nearly to the same extent as SH2B1β (FIG. 3.9).  This 
result suggests that there are properties of the unique SH2B1α C-terminal tail 
that are preventing nuclear entry of SH2B1 and the enhancement of NGF-
































FIG. 3.9. SH2B1 1-620 enhances NGF-induced PC12 cell neurite outgrowth. 
PC12 cells expressing GFP, GFP-SH2B1β WT, or GFP-SH2B1 1-620 were 
treated with NGF (25 ng/ml) to induce differentiation. Neurites > 2X cell body 






 It has been shown previously that SH2B1β is able to enhance NGF-
mediated differentiation and that the nuclear-cytoplasmic shuttling of SH2B1β 
appears to be required for this enhancement (62).  In this report, we show that 
SH2B1α, in contrast to SH2B1β, does not enhance NGF-induced PC12 cell 
neuronal differentiation. 
 Although SH2B1α is capable of promoting the autophosphorylation of 
JAK2 and the insulin-stimulated tyrosyl phosphorylation of IRS2 to the same 
extent as SH2B1β, SH2B1α is unable to enhance NGF-induced neuronal 
differentiation.  We showed that SH2B1α is unable to enter the nucleus with LMB 
treatment in 293T cells and does not enhance the expression of a sub-set of 
NGF-induced genes required for neuronal differentiation.  We have also provided 
evidence that it is most likely the unique C-terminal tail of SH2B1α that prevents 
its ability to enhance neuronal differentiation.   
These data suggest that SH2B1α does not play a role in neuronal 
differentiation (at least under our conditions in PC12 cells), which is supported by 
the fact that patients with SH2B1 mutations that would only be present in the 
alpha isoform due to alternative splicing (A663V, V695M, and A723V) do not 
present with abnormal neurobehavioral phenotypes.  While these patients are 
still obese and insulin resistant, which suggests that SH2B1α is important for 
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whole-body energy homeostasis and insulin sensitivity, they do not display the 
maladaptive behavior phenotype seen in patients with SH2B1 human mutations 
that are present in the beta, gamma, or delta isoforms (all capable of enhancing 
NGF-induced neuronal differentiation).  This suggests that there is another 
pathway or brain cell type that is affected by SH2B1α to influence whole-body 
energy homeostasis.  
It will be important to understand how the unique C-terminal tail of 
SH2B1α acts to prevent SH2B1α from entering the nucleus, which may provide 
insight into how other proteins have their nuclear entry regulated.  It seems likely 
that a great deal can be learned about the processes governing neuronal 
differentiation by investigating the signaling pathways and transcription factors 
that are differentially regulated by SH2B1α and SH2B1β.  This insight may lead 
to the identification of targets for therapeutics that promote the positive regulation 















Effects of human mutations on cellular actions of SH2B1 delta 
Abstract 
SH2B1 modulates signaling by a variety of ligands that bind to receptor tyrosine 
kinases or JAK-associated cytokine receptors, including receptors for leptin, 
insulin, growth hormone (GH), and nerve growth factor (NGF).  Targeted deletion 
of Sh2b1 in mice results in increased food intake, obesity, and insulin resistance, 
with an intermediate phenotype seen in heterozygous null mice on a high-fat diet.  
SH2B1 is expressed as four different isoforms: alpha, beta, gamma, and delta.  
Previously, SH2B1 loss-of-function mutations have been identified in a large 
cohort of patients with severe early-onset obesity and the effects of these 
mutations on cellular actions of SH2B1β were investigated.  Here, we identify 
additional mutations present in SH2B1 from obese patients with disproportionate 
insulin resistance, including one mutation exclusive to the delta isoform.  We 
show that SH2B1δ has a sub-cellular localization at the plasma membrane and 
nucleolus and that a bipartite NLS in the unique C-terminal tail of SH2B1δ is 
important for its nucleolar localization and enhancement of NGF-induced neurite 
outgrowth.  We show that SH2B1δ with one of the human mutations does not 
enhance NGF-induced neurite outgrowth to same extent as SH2B1δ WT.  
However, we did not see a difference between the ability of SH2B1δ WT or 
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mutant to enhance JAK2 activation or enhance NGF-induced ERK 1/2 



























Recently, SH2B1 has been identified as a human obesity gene.  Humans 
with point mutations found in SH2B1 exhibit severe early-onset obesity, extreme 
insulin resistance, and maladaptive behavior (112).  The hyperphagia and 
maladaptive behavior seen in these patients hint at a possible role for SH2B1 in 
neuronal development.  This is supported by the effects of neuronal SH2B1 in 
mice with a whole-body knockout of Sh2b1.  Sh2b1-/- mice are obese and insulin 
resistant (18), yet when transgenic mice are created using a neuronal-specific 
enolase promoter to express SH2B1β mainly in neurons, the metabolic disorder 
phenotype is ameliorated (54).     
The adaptor protein SH2B1 is expressed as four different isoforms (alpha, 
beta, gamma and delta) that arise due to alternative splicing (28, 29).  The 
SH2B1 isoforms are identical in their sequence until variable splice sites produce 
unique C-terminal tails for each.  While the beta isoform has been well 
characterized, there has not been much investigation into the 110-kDa delta 
isoform.  
SH2B1δ has been seen to behave similarly to SH2B1β in promoting 
mitogenesis and cell survival in NIH 3T3 fibroblasts (28), and insulin receptor 
kinase activity in 3T3-L1 adipocytes (49).  SH2B1β and γ have been reported to 
enhance nerve growth factor (NGF)-induced PC12 cell neuronal differentiation 
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(30, 31), in part by promoting the expression of a sub-set of NGF-induced genes 
required for differentiation (67).  Nuclear-cytoplasmic shuttling of SH2B1β 
appears to be required for this enhancement of NGF-induced neuronal 
differentiation (62).  Human mutations identified in SH2B1 impair the ability of 
SH2B1β to enhance NGF-induced neuronal differentiation (112).   
The unique C-terminal tail of SH2B1δ contains a putative bipartite nuclear 
localization signal (NLS) that may confer a unique sub-cellular localization for 
SH2B1δ compared to the primarily plasma membrane (PM) and cytosolic steady-
state localization of SH2B1β.  The human mutations reported previously to affect 
SH2B1β function are also present in SH2B1δ and, recently, more mutations have 
been identified that are only expressed in the alpha or delta isoforms.  It appears 
that the expression of SH2B1δ is limited to brain tissues (112).  Thus, it is 
important to better understand the cellular functions of SH2B1δ in neuronal 
processes and, particularly, how these are affected by the human mutations.    
 In this report, we show that the putative bipartite NLS is responsible for the 
nuclear/nucleolar localization of SH2B1δ and that intact NLS motifs are required 
for SH2B1δ to promote neuronal differentiation.  We also characterize the effects 
of SH2B1δ WT or SH2B1δ with human mutations on NGF-induced neuronal 









Materials and Methods 
Antibodies and Reagents.  αFLAG (M2) (1:2000) (α = antibody) was 
from Sigma.   αJAK2 p1007/1008 (1:1000) was from Upstate Biotechnology Inc. 
(Lake Placid, NY).  αERK1/2 and αERK1/2 pT202/Y204 (1:1000) were from Cell 
Signaling Technology (Beverly, MA). IRDye800-conjugated anti-GFP, IRDye700 
and IRDye800 conjugated anti-mouse and anti-rabbit IgG (Rockland 
Immunochemicals, Gilbertsville, PA) were used at a dilution of 1:20,000.  NGF 
and rat-tail collagen I were purchased from BD Bioscience (San Diego, CA).     
Plasmids.  Murine SH2B1δ (accession# AF380422) and rat SH2B1β 
(NM_001048180) were cloned into the pEGFP C1 vector (Clontech, Mountain 
View, CA) (described previously (62)) and pmCherry C1 vector (Clontech).  
Mutations were introduced using the QuickChange Mutagenesis kit (Stratagene).  
GFP-Nucleolin (114) was from Addgene (Cambridge, MA) (Addgene plasmid 
28176).  All constructs were verified by sequencing. 
Cell Culture and Cell Lines.  The parental PC12 cells were obtained 
from American Type Culture Collection (ATCC) (Rockville, MD).  PC12 cells were 
plated on collagen-coated plates (0.1 mg/ml rat tail collagen in 0.02 N acetic 
acid) and grown at 37°C in 5% CO2 in normal growth medium containing RPMI 
1640 (ATCC), 10% heat-inactivated horse serum (Invitrogen), and 5% fetal 
bovine serum (Atlanta Biologicals).  PC12 cells were transfected using a Gene 
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Pulser Xcell Electroporator (400V, 500µF) in a 0.4 cm cuvette (Bio-Rad).  293T 
cells (from Dr. O. A. MacDougald, University of Michigan, Ann Arbor, MI) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 8% calf serum 
(Atlanta Biologicals) and transfected using calcium phosphate. 
Confocal Microscopy.  Cell imaging was performed using an Olympus 
FluoView 500 laser scanning confocal microscope and FluoView version 5.0 
software.  Transfected 293T cells were plated on poly-d-lysine coated glass 
bottom dishes (MatTek, Ashland, MA) and imaged while in Ringer’s buffer (10 
mM HEPES, 155 mM NaCl, 2 mM CaCl2, 5 mM KCl, 1 mM MgCl2, 10 mM 
NaH2PO4 and 10 mM glucose, pH 7.2). The plasma membrane was labeled with 
wheat germ agglutinin-conjugated Alexa Fluor 647 (Invitrogen). 
Differentiation of PC12 cells.  PC12 cells were grown on collagen-
coated 10-cm2 dishes then plated on collagen-coated 60-mm2 dishes after 
transfection. 24 h post transfection, 25 or 50 ng/ml NGF was added to RPMI 
1640 containing 5% horse serum, 1% FBS to induce PC12 cell differentiation.  
NGF-containing differentiation medium was refreshed two days later.  The cells 
were visualized by fluorescence microscopy (Nikon Eclipse TE200).  The percent 
of GFP+ cells that were differentiated (neurite outgrowths >2 times the length of 
the cell body) was determined. 
 Cell lysis and immunoblotting.  Cells were solubilized in sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) sample lysis buffer (50 
mM Tris [pH 7.5], 1% SDS, 0.001% bromophenol blue, 10% glycerol, 0.1% Triton 
X-100, 150 mM NaCl, 2 mM EGTA) and proteins were separated by SDS-PAGE.  
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Proteins in the gel were transferred to a nitrocellulose membrane and detected 
by immunoblotting with the indicated antibodies.  Blots were then incubated with 
infrared dye-conjugated secondary antibodies and visualized using the Odyssey 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). 
qPCR.  Total RNA was isolated using Stat60 (Tel-Test) and cDNA was 
generated using TaqMan Reverse Transcription kit (Applied Biosystems, 
Branchburg, NJ).  Gene expression was assessed using SYBR Green (Bio-Rad) 
and the Eppendorf Mastercycler ep (Hamburg, Germany).  All readings were 
normalized to the expression of glyceraldehyde-3- phosphate dehydrogenase 



















C-Terminal bipartite NLS regulates nuclear/nucleolar localization of 
SH2B1δ.  The N-terminal NLS (termed NLS1), which is common to all SH2B1 
isoforms, has been shown to be required for SH2B1β to enter the nucleus (62).  
The unique C-terminal tail region of SH2B1δ contains two stretches of basic 
amino acids proximal to each other (termed NLS2 and NLS3, respectively) that 
closely resemble a bipartite nuclear localization sequence motif (115).  A bipartite 
NLS motif has been shown to promote protein sub-cellular localization in the 
nucleolus (116).  The nucleolus is a distinct region in the nucleus that is the main 
site of ribosome biosynthesis (117, 118) and RNA processing (119).  The 
nucleolus has also been implicated in the regulation of the cell cycle (120), 
tumorigenesis (121) and viral replication (122).  We first used confocal 
microscopy of living cells to look at the localization of cherry-SH2B1δ.  In contrast 
to SH2B1β which localizes to the PM and cytosol, SH2B1δ WT was localized to 
the nucleolus; a small amount was also present in the PM, which was visualized 
with higher exposure duration.  To investigate the role of the three NLS motifs in 
SH2B1δ sub-cellular localization, four basic amino acid residues in each NLS 
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FIG. 4.1. Schematic of SH2B1δ NLS mutations.  P, proline-rich region; DD, 
dimerization domain; NLS, nuclear localization sequence; NES, nuclear export 
sequence; PH, pleckstrin homology domain.  Lys or Arg from the WT NLS 
sequences (black) were mutated to Ala or Gly (red). 
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An intact NLS1 has also been shown to be required for SH2B1β to go to 
both the nucleus the PM (65).  Thus, we would predict that any SH2B1δ 
construct with a mutated NLS1 would not localize at the PM.  Since SH2B1δ is 
the only SH2B1 isoform with a C-terminal bipartite NLS motif and is the only 
isoform seen to localize at the nucleolus, we also predicted that disruption of 
NLS2 and NLS3 would prohibit nucleolar localization of SH2B1δ.  The steady-
state sub-cellular localization of each SH2B1δ construct was determined in living 
cells using confocal microscopy.  Both SH2B1δ mNLS1 and mNLS2 were 
localized at the nucleolus, similar to WT, but SH2B1δ mNLS1 was no longer 
present at the PM. SH2B1δ mNLS3 is seen localized at the nucleoplasm (as 
opposed to specifically at the nucleolus) and PM to a greater extent than WT.  
SH2B1δ mNLS2/3 was excluded from the nucleus but present at the PM.  
SH2B1δ mNLS1/2/3 appeared to potentially be toxic when overexpressed as the 
cells looked unhealthy when imaged and displayed a variable sub-cellular 
localization (seen with diffuse or aggregate localization) (FIG. 4.2).   
These results suggest that an intact NLS1 is required for SH2B1δ to 
localize to the PM and that when NLS1 is intact, only one of the C-terminal NLS 
motifs is required for steady-state nuclear/nucleolar localization of SH2B1δ.  
However, these results also indicate that an intact bipartite NLS is not required 
for nucleolar steady-state localization of SH2B1δ as SH2B1δ mNLS2 and 
mNLS3 exhibited steady-state localization in the nucleolus.  This may suggest 







GFP-­Nucleolin   WGA   Overlay  
Cherry-­empty  vector  
Cherry-­SH2B1   WT  
Cherry-­SH2B1   mNLS  1  
Cherry-­SH2B1   mNLS  2  
FIG. 4.2.  SH2B1δ requires NLS1 to localize at the PM and both 
components of the bipartite NLS to localize at the nucleolus.  293T cells 
transiently expressing Cherry-SH2B1 and GFP-Nucleolin (protein marker of the 
nucleolus) were stained with the plasma membrane wheat germ agglutinin 
Alexa Fluor 647 and imaged using fluorescent confocal microscopy.  Cherry = 
red, GFP-Nucleolin = green, Wheat Germ Agglutinin (WGA) = blue.  Scale bars: 
10 µm. (A) Cherry-empty vector depicts a diffuse sub-cellular localization, but 
not at the nucleolus. (B) Cherry-SH2B1δ WT appears localized at the nucleolus. 
(C) Cherry-SH2B1δ mNLS 1 localizes at the nucleolus. (D) Cherry-SH2B1δ 






GFP-­Nucleolin   WGA   Overlay  
Cherry-­SH2B1   mNLS  3  
Cherry-­SH2B1   mNLS  2/3  
Cherry-­SH2B1   WT  
FIG. 4.2.  SH2B1δ requires NLS1 to localize at the PM and both 
components of the bipartite NLS to localize at the nucleolus.  293T cells 
transiently expressing Cherry-SH2B1 and GFP-Nucleolin (protein marker of the 
nucleolus) were stained with the plasma membrane (pm) dye wheat germ 
agglutinin Alexa Fluor 647 and imaged using fluorescent confocal microscopy.  
Cherry = red, GFP-Nucleolin = green, Wheat Germ Agglutinin (WGA) = blue.  
Scale bars: 10 µm. (E) Cherry-SH2B1δ mNLS3 depicts a nucleolar and pm sub-
cellular localization. (F) Cherry-SH2B1δ mNLS 2/3 localizes at the pm. (G) 







WGA   Overlay  
Cherry-­SH2B1   WT  
Cherry-­SH2B1   mNLS  1  
Cherry-­SH2B1   mNLS  2  
FIG. 4.2.  SH2B1δ requires NLS1 to localize at the PM and both 
components of the bipartite NLS to localize at the nucleolus.  293T cells 
transiently expressing Cherry-SH2B1 and GFP-Nucleolin (protein marker of the 
nucleolus) were stained with the plasma membrane wheat germ agglutinin 
Alexa Fluor 647 and imaged using fluorescent confocal microscopy.  Cherry = 
red, GFP-Nucleolin = green, Wheat Germ Agglutinin (WGA) = blue.  Scale bars: 
10 µm. (I) Cherry-SH2B1δ WT appears localized at the pm when imaged at a 
high exposure. (J) Cherry-SH2B1δ mNLS 1 was not detected at the pm even 
when imaged using a high exposure. (K) Cherry-SH2B1δ mNLS 2 appears 
localized at the pm when imaged at a high exposure.  Yellow arrows indicate pm 
localization determined by a purple signal representing co-localization of Cherry-
SH2B1δ and WGA. 
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localization but because SH2B1δ mNLS 2/3 was excluded from the nucleus 
entirely, there may be still unidentified regions of the SH2B1δ C-terminal tail 
responsible for the direct nucleolar localization of SH2B1δ.    
     Intact NLS motifs are required for SH2B1δ to enhance NGF-induced 
neuronal differentiation.  To assess whether SH2B1δ, like SH2B1β, enhances 
NGF-induced neuronal differentiation, PC12 cells were transiently transfected 
with either empty-vector Cherry plasmid, or Cherry-tagged SH2B1β WT or 
SH2B1δ WT and treated with NGF to initiate differentiation.  The PC12 cell line 
has been commonly used as a model system to investigate the mechanisms of 
NGF-mediated neuronal differentiation and NGF signal transduction (86).  RNAi 
experiments have shown that SH2B1 is required for NGF-induced neurite 
outgrowth (67).  PC12 cells are derived from a solid rat pheochromocytoma 
tumor and, when treated with NGF, differentiate into a neuronal type cell with 
properties similar to those of sympathetic neurons (87).  When PC12 cells are 
treated with NGF, they stop proliferating and initiate a differentiation process in 
which they exhibit cellular hypertrophy, produce neurite outgrowths, express 
neuronal-specific markers, and become electrically excitable (86, 87).  
Differentiated sympathetic-like PC12 neuronal cells are able to form synapses 
with primary neurons (88), supporting the biological relevance of this in vitro cell 
line.  SH2B1δ WT, like SH2B1β, promoted a large enhancement of NGF-induced 






































FIG. 4.3. SH2B1δ WT, but not with a mutated NLS, enhances NGF-induced 
PC12 cell differentiation to the same extent as WT.  PC12 cells transiently 
expressing cherry-tagged SH2B1δ or SH2B1βWT, or SH2B1δ a mutant NLS 
were treated with NGF (25 ng/ml) to induce differentiation. Percent differentiated 
values were normalized against WT at day 1 of differentiation (means ± SEM). 
The fractions of GFP+ cells that were differentiated at each day of differentiation 
were counted (a cell was scored as differentiated if the length of its neurite 
outgrowths were greater than two-times the length of the cell body).   Percent 
differentiated values were normalized against SH2B1δ WT at day 1 of 
differentiation (means ± SEM).  All mutants impaired the rate of NGF-induced 
neuronal differentiation compared to SH2B1δ and SH2B1β WT.  SH2B1δ and 
SH2B1β WT vs. others, **p < 0.0001, 1-way ANOVA with Dunnett’s post-test, n 
= 3-4 separate experiments.  NOTE: SH2B1δ and SH2B1β WT are statistically 
significantly different than SH2B1δ mNLS 1, mNLS 2, or mNLS 3 at day 3 of 
differentiation. 
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if the length of its neurite outgrowths were greater than two-times the length of 
the cell body).   
Since nuclear shuttling is required for SH2B1β to enhance NGF-induced 
neuronal differentiation, we predicted that SH2B1δ with NLS mutations that 
exclude it from the nucleus would also fail to enhance NGF-induced neuronal 
differentiation.  To determine whether sub-cellular localization of SH2B1δ is 
important for NGF-induced neuronal differentiation, PC12 cells were also 
transfected with Cherry-tagged SH2B1δ mNLS1, SH2B1δ mNLS2, SH2B1δ 
mNLS3, SH2B1δ mNLS2/3, or SH2B1δ mNLS1/2/3 and treated with NGF to 
initiate differentiation.    SH2B1δ mNLS1, mNLS2, and mNLS3 were able to 
enhance differentiation but not to the same extent as WT.  SH2B1δ WT mNLS2/3 
and mNLS1/2/3 failed to promote NGF-induced neuronal differentiation (FIG 4.3).  
These results suggest that mutations that exclude SH2B1δ from the nucleus 
inhibit NGF-induced differentiation while mutations that do not exclude SH2B1δ 
from the nucleus are still able to promote NGF-induced neuronal differentiation, 
although at an impaired rate compared to WT. 
SH2B1δ with human mutations do not enhance NGF-induced 
neuronal differentiation to the same extent as SH2B1δ WT.  The human 
mutations identified previously to affect the function of SH2B1β are also present 
in SH2B1δ.  Since the publication of the initial report to characterize human 
mutations in SH2B1, more mutations in SH2B1 from patients with early onset 
obesity and extreme insulin resistance have been identified.  Most of the 
identified mutations are common to all SH2B1 isoforms.  These include the 
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previously reported P90H, T175N, P322S, F344LfsX20, and the novel A484T 
(which is possibly a single-nucleotide polymorphism) and T546A mutations.  
However, some mutations have been identified that are present in only SH2B1 
alpha or delta transcripts.  In SH2B1δ, these mutations are R680C (an A663V 
mutation in the alpha isoform) and P712P.  The P712P mutation (which is V695M 
in the alpha isoform) contains a nucleotide change that does not lead to an actual 
amino acid change in SH2B1δ.  The resulting codon still produces a Pro (FIG. 
4.4).   
To assess the effects of the human mutations in SH2B1δ on NGF-induced 
neurite outgrowth, PC12 cells were transiently transfected with GFP, GFP-
SH2B1δ WT, or GFP-SH2B1δ with a human mutation.  SH2B1δ with the human 
mutations P90H, T175N, P322S, T546A, and R680C (which is located in the C-
terminal tail and is unique to SH2B1δ) all show impaired enhancement of NGF-
induced neuronal differentiation, while SH2B1δ A484T and P712P enhanced 
NGF-induced neuronal differentiation to a similar extent as SH2B1δ WT (FIG. 
4.5), indicating that an alteration alone in the nucleotide sequence of SH2B1 
without a change in the protein sequence is not sufficient to cause dysfunction of 
SH2B1.  
SH2B1δ enhances ERK phosphorylation in response to NGF.  A 
sustained ERK phosphorylation in response to NGF is associated with PC12 cell 
differentiation while more transient ERK phosphorylation (as seen in response to 
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FIG. 4.4. Identification of human mutations in SH2B1δ.  P, proline-rich 
region; DD, dimerization domain; NLS, nuclear localization sequence; NES, 
nuclear export sequence; PH, pleckstrin homology domain, unique SH2B1δ C-
terminal tail in orange. SH2B1δ mutations are shown in boxes. 
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FIG. 4.5. SH2B1δ with disease-causing human mutations do not enhance 
NGF-induced PC12 cell differentiation to the same extent as WT.  PC12 
cells transiently expressing GFP-tagged WT or mutant SH2B1δ were treated 
with NGF (25 ng/ml) to induce differentiation.   The fractions of GFP+ cells that 
were differentiated at each day of differentiation were counted with means ± 
SEM shown (a cell was scored as differentiated if the length of its neurite 
outgrowths were greater than two-times the length of the cell body). All mutants 
impaired the rate of NGF-induced neuronal differentiation compared with WT. 
SH2B1δ WT, A484T, and P712P vs. others, ***p < 0.0001, 1-way ANOVA with 
Bonferroni's multiple comparison post-test, n = 3 separate experiments. 
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to see whether SH2B1δ altered ERK phosphorylation and whether the human 
mutations impaired ERK phosphorylation in response to NGF.  To carry out these 
studies, PC12 cells stably expressing GFP, GFP-SH2B1β WT, GFP-SH2B1δ 
WT, GFP-SH2B1δ P322S, or GFP-SH2B1δ R680C were created (FIG. 4.6).   
The stably transfected PC12 cells were treated with NGF (25 ng/ml) for 5 
and 30 minutes.  Cell lysates were immunoblotted with a phospho-specific 
antibody that recognizes the doubly phosphorylated, active forms of ERKs 1/2.  
SH2B1β did not affect NFG activation of ERKs as reported previously (31).  In 
contrast to SH2B1β, SH2B1δ-expressing cells exhibited an increased and 
prolonged level of NGF-dependent ERK phosphorylation compared to GFP-
expressing cells (FIG. 4.7).  To see if the human mutations impair the ability of 
SH2B1δ to enhance NGF-induced ERK phosphorylation, GFP-SH2B1δ WT, 
P322S and R680C expressing PC12 cells were treated with NGF (25 ng/ml) for 
5, 120, and 240 minutes.  At each time point, SH2B1δ P322S and R680C 
enhanced ERK phosphorylation to the same extent as SH2B1δ WT (FIG. 4.8). 
SH2B1δ enhances NGF-induced gene expression.  Overexpression of 
SH2B1β has been shown to enhance the expression of a sub-set of NGF-
induced genes in PC12 cells.  This enhancement of gene expression is 
associated with enhancement of neuronal differentiation (67).  Among the sub-
set of NGF-induced genes, Plaur, Mmp3, and Mmp10, encoding urokinase 
plasminogen activator receptor (uPAR), matrix metalloproteinase (MMP)-3 
(stromelysin-1; transin-1), and MMP10 (stromelysin-2; transin-2), respectively, 
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FIG. 4.6. PC12 cells stably express GFP-SH2B1β, or GFP-SH2B1δ WT, 
P322S, or R680C.  Proteins in lysates from PC12 cells stably expressing GFP, 
GFP-SH2B1β, GFP-SH2B1δ WT, GFP-SH2B1δ P322S, or GFP-SH2B1δ 
R680C were separated by SDS-PAGE and immunoblotted with α-SH2B1.  
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FIG. 4.7. SH2B1δ, but not SH2B1β, enhances NGF-induced ERK 
phosphorylation.  Proteins in lysates from PC12 cells stably expressing GFP, 
GFP-SH2B1β, or GFP-SH2B1δ and treated with NGF (25 ng/ml) for the 
indicated time were separated by SDS-PAGE and immunoblotted with α-GFP 










































































FIG. 4.8. SH2B1δ P322S and R680C enhance NGF-induced ERK 
phosphorylation to the same extent as SH2B1δ WT.  Proteins in lysates from 
PC12 cells stably expressing GFP, GFP-SH2B1δ WT, P322S, or R680C and 
treated with NGF (25 ng/ml) for the indicated time were separated by SDS-
PAGE and immunoblotted with α-GFP (top panel), α-pERK 1/2 (middle panel), 
or α-ERK 1/2 (bottom panel). 
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expression.  This cluster of genes is important for extra-cellular matrix 
degradation and neurite extension associated with neuronal differentiation (68-
71).  Because SH2B1δ, like SH2B1β, enhances neurite outgrowth, we 
investigated whether overexpression of SH2B1δ, like overexpression of SH2B1β, 
enhances NGF-induced expression of Plaur, Mmp3, and Mmp10.  The PC12 cell 
lines expressing GFP, GFP-SH2B1β WT, or GFP-SH2B1δ WT were treated for 
six hours with NGF (25 ng/ml) and relative levels of MMP3, MMP10, and uPAR 
mRNA were assessed by qPCR.  Consistent with previous results, SH2B1β 
enhanced NGF-induced expression for all three genes.  SH2B1δ also enhanced 
expression of these three genes, however levels of enhancement of NGF-
induced gene expression from all conditions were highly variable and there was 
no significant difference detected in the ability to enhance NGF-induced gene 
expression between WT and SH2B1δ P322S and R680C (FIG. 4.9).  This 
suggests that SH2B1δ may be acting similarly to SH2B1β to regulate gene 
expression in the nucleus in response to NGF but more experiments are required 
to determine whether SH2B1δ P322S and R680C actually impair SH2B1δ 
enhancement of NGF-induced gene expression.     
SH2B1δ enhances JAK2 autophosphorylation.  SH2B1β was originally 
identified as a binding partner for the receptor-associated tyrosine kinase JAK2 
(22).  Many cytokine and growth factor receptors utilize JAK2 to mediate their 
signal transduction, including the receptors for growth hormone (GH) and leptin.  

















































































































































FIG. 4.9. Overexpression of 
SH2B1δ WT or with a human 
mutation promotes NGF-
induced expression of MMP3, 
and MMP10 mRNA expression.  
PC12 cells stably expressing 
GFP, or GFP-tagged SH2B1β 
WT, SH2B1δ WT, SH2B1δ 
P322S, or SH2B1δ R680C were 
NGF (25 ng/mL) for 6 hours.  
Relative mRNA levels were 
determined using qPCR, 
normalized to levels of GAPDH 
mRNA and then to the mRNA 
levels in NGF-treated GFP 
control cells.  Means ± SEM 
(n=3).  Due to high variability 
between assays none the values 
are statistically significantly 
different from each other.  More 
experiments are required. 
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enhance JAK2 tyrosine kinase signaling activity.  This requires an intact SH2 
domain of SH2B1β to bind to phospho-tyrosine 813 of JAK2 (40, 113).  To 
determine whether SH2B1δ, like SH2B1β, activates JAK2, 293T cells were 
transiently transfected with cDNA encoding Flag-tagged JAK2 and GFP-tagged 
SH2B1β WT or SH2B1δ WT.  JAK2 activity was assessed by blotting with α-
pJAK2 Y1007/1008, which recognizes the active form of JAK2.  SH2B1δ WT is 
able to enhance JAK2 activity, similarly to what is seen when JAK2 is co-
expressed with SH2B1β (FIG. 4.10).   
Next we tested whether human mutations identified in SH2B1 impaired the 
ability of SH2B1δ to activate JAK2.  SH2B1δ with human mutations P90H, 
T175N, P322S, A484T, T546A, R680C, and P712P enhanced JAK2 activity to a 
similar extent as SH2B1δ WT (FIG. 4.11).  All mutants expressed at the expected 
size and at similar levels.  While subtle differences in the ability to activate JAK2 
may be masked in this assay by overexpression of SH2B1δ and JAK2, these 
results are consistent with both SH2B1β and SH2B1α with human mutations 
enhancing JAK2 activity to the same extent as WT (unpublished observations, 
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FIG. 4.10. SH2B1δ enhances JAK2 phosphorylation.  Proteins in lysates 
from 293T cells transiently expressing Flag-JAK2 and GFP-SH2B1δ were 
separated by SDS-PAGE and immunoblotted with α-GFP (top panel), α-
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FIG. 4.11. SH2B1δ with a human mutation enhances JAK2 
phosphorylation to the same extent as SH2B1δ WT.  Proteins in lysates from 
293T cells transiently expressing Flag-JAK2 and GFP-SH2B1δ WT, P90H, 
T175N, P322S, A484T, T546A, R680C, and P712P were separated by SDS-
PAGE and immunoblotted with α-GFP (top panel), α-JAK2pY1007 (middle 






 We have shown previously that SH2B1β enhances NGF-mediated neurite 
outgrowth of PC12 cells and that the nuclear-cytoplasmic shuttling of SH2B1β 
appears to be required for this enhancement.  In contrast to SH2B1β, which is 
widely expressed, previous results indicate SH2B1δ may have its expression 
limited to brain tissues (112).  Here, we show that SH2B1δ has a steady-state 
sub-cellular localization at the nucleolus and PM.  Activation of ribosome 
biosynthesis at the nucleolus is sufficient to cause cellular hypertrophy and 
neurite outgrowth in neuronal cells (123).  Together, these findings suggest that 
nucleolar SH2B1δ may be playing a role in neuronal differentiation.   
We confirmed that the putative bipartite NLS in the unique C-terminal tail 
of SH2B1δ is responsible for the steady-state nuclear/nucleolar sub-cellular 
localization of SH2B1δ.  We also showed that similar to SH2B1β (65), the NLS1 
of SH2B1δ is required for PM localization.  We then showed that mutating NLS 1, 
2, or 3 partially prevented SH2B1δ enhancement of NGF-induced neurite 
outgrowth, suggesting that PM localization and nuclear shuttling of SH2B1δ are 
required to fully enhance NGF-induced PC12 cell differentiation.  These data are 
consistent with the notion that the actions of SH2B1 in the nucleus and at the PM 
are critical for the promotion of NGF-induced neuronal differentiation.  While it is 
clear that the bipartite NLS of SH2B1δ directs its steady-state localization at the 
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nucleus, it remains unclear which region of the SH2B1δ C-terminal tail is directly 
responsible for localizing SH2B1δ at the nucleolus.  SH2B1δ mNLS2 and mNLS3 
still localized at the nucleolus, but mNLS2/3 was excluded from nucleus.  No 
SH2B1δ cDNA construct tested displayed a nuclear but non-nucleolar SH2B1δ 
localization.  RNA-binding motifs (stretches of aromatic amino acids) and 
glycine/arginine-rich (GR) domains have been implicated in targeting nuclear 
proteins to the nucleolus (124).  The SH2B1δ C-terminal tail contains a Trp-rich 
region as well as GR segments within the bipartite NLS (28).  Analysis of sub-
nuclear localization of a series of deletion mutations should help to elucidate the 
region of the SH2B1δ C-terminal tail responsible for localizing SH2B1δ at the 
nucleolus. 
We also describe the ability of SH2B1δ to enhance NGF-induced PC12 
cell neuronal differentiation and the inability of mutant SH2B1δ to enhance the 
rate of differentiation to the same extent as WT.  SH2B1β and SH2B1δ promoted 
similar rates of enhanced NGF-induced neuronal differentiation.  As more and 
more subjects have their SH2B1 gene sequenced, it appears that A484T may 
just be a single nucleotide polymorphism (SNP) and not a disease-causing 
mutation (I. Sadaf Farooqi, personal communication).  Our results are consistent 
with A484T being a non-disease causing SNP as SH2B1δ A484T was able to 
enhance differentiation to a similar extent as WT.  The mutations shared among 
all isoforms of SH2B1 (P90H, T175N, P322S, T546A) and the delta-specific 
mutation, R680C, exhibited impaired enhancement of NGF-induced neuronal 
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differentiation, similar to what has been reported for human mutations in the beta 
isoform (112).   
Nuclear accumulation is impaired in SH2B1β with human mutations, 
possibly explaining why those mutants are unable to promote neuronal 
differentiation to the same extent as SH2B1β WT.  In contrast, SH2B1δ with a 
human mutation is constitutively present in the nucleus/nucleolus and at the PM 
(data not shown).  Thus, a similar explanation is unlikely to hold for why SH2B1δ 
mutations impair its ability to enhance NGF-induced neurite outgrowth.  Thus, we 
assayed for SH2B1δ activation of ERKs 1/2, which is critical to PC12 cell 
differentiation.  In contrast to SH2B1β, SH2B1δ promoted an enhanced and 
sustained level of ERK 1/2 phosphorylation.  Thus, the enhanced response could 
be due to an enhanced ERK 1/2 response.  However, SH2B1δ P322S and 
R680C promoted a similar level of ERK 1/2 phosphorylation as SH2B1δ WT, so 
we cannot explain the impaired NGF-induced neuronal differentiation seen with 
SH2B1δ mutants by an impaired ERK 1/2 activation.   
SH2B1β has been shown to enhance the expression of a sub-set of NGF-
induced genes that are important for neurite outgrowth.  We show that SH2B1δ is 
able to promote an enhancement of expression of the NGF-induced genes 
Mmp3, Mmp10 and Plaur.  Surprisingly, SH2B1δ P322S and R680C promoted a 
similar level of NGF-induced gene expression as WT.  More experiments are 
needed to provide statistically significant results.  These results suggest that 
human mutations in SH2B1δ might impair NGF-induced expression of other 
genes or impair NGF-induced differentiation by a different mechanism. 
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Unlike SH2B1β with human mutations that exhibits impaired nuclear 
accumulation, a mechanism by which SH2B1δ with a human mutation leads to 
impaired enhancement of neuronal differentiation has yet to be identified.  It may 
be that the human mutations are affecting the ability of SH2B1δ to regulate a 
signaling pathway or cell process not yet identified to be regulated by SH2B1, 
most likely a signaling event downstream or independent of ERKs.  To fully 
understand the role SH2B1 plays in the regulation of neuronal differentiation, it is 
crucial to identify binding partners of SH2B1 in the nucleus of neurotrophin-
stimulated cells.      
In summary, SH2B1δ has been identified as a nucleolar protein that is a 
positive regulator of NGF-induced neuronal differentiation, ERK phosphorylation, 
and gene expression.  Nuclear localization of SH2B1δ is important for the 
enhancement of neuronal differentiation.  Human mutations identified in SH2B1 
and introduced into SH2B1δ exhibit an impaired ability to promote NGF-induced 
differentiation compared to WT, yet are able to enhance ERK phosphorylation 
and gene expression in response to NGF to a similar extent as SH2B1δ WT.  
Thus, the mechanism by which the human mutations impair the ability of SH2B1δ 











The adapter protein SH2B1 and growth hormone-induced gene expression 
Abstract 
Metabolic effects of growth hormone (GH) in adipose tissue have been shown to 
be mediated, at least in part, by changes in gene expression. The adapter protein 
SH2B1 is a signaling molecule for many cytokines and growth factors, including 
GH. SH2B1 is recruited to the GH- activated form of the GH receptor-associated 
tyrosine kinase JAK2, resulting in its phosphorylation by JAK2 on tyrosines and 
on serine/threonines by other kinases. SH2B1 has been implicated in GH 
regulation of the actin cytoskeleton. Recently, our laboratory has identified both a 
nuclear localization signal (NLS) and nuclear export sequence (NES) in SH2B1. 
SH2B1 constitutively shuttles in and out of the nucleus, even though its steady-
state sub-cellular localization is mostly in the plasma membrane and cytosol. In 
PC12 neuronal cells stimulated with nerve growth factor (NGF), over-expression 
of wild-type SH2B1, but not SH2B1 that is incapable of entering the nucleus 
(SH2B1 mNLS), enhances the expression of a sub-set of NGF-induced genes. 
Together, these data led us to hypothesize that SH2B1 regulates GH-induced 
gene expression in adipocytes. To test this, cultured 3T3-F442A adipocytes with 
endogenous SH2B1 knocked-down by RNAi and control cells were stimulated 
with GH for 1 h and a sub-set of genes that depend on SH2B1 for their full GH-
 101 
induced expression was identified by microarray analysis. Of the 16,361 total 
genes on the array, 611 were up-regulated by GH at least 60%; of those genes, 
247 appeared to depend on SH2B1 for their full GH-induced expression. GH-
dependent expression of Apelin, Cish and Arid5a genes and their decreased GH-
induced expression in cells with decreased levels of SH2B1 were confirmed by 
qPCR. The re-introduction of SH2B1 in 3T3-F442A preadipocytes in which 
endogenous SH2B1 is knocked-down is able to rescue GH-induced expression 
of Cish and Arid5a. Overexpression of SH2B1, but not SH2B1 mNLS, enhances 
GH-induced expression of these genes. These results are consistent with SH2B1 
being required for maximal expression of a sub-set of GH-dependent genes. 
Further, nuclear localization of SH2B1 may be required for SH2B1 enhancement 

















Growth hormone (GH) regulates multiple physiological functions, including 
body growth and metabolism.  Among its best characterized metabolic actions 
are its ability to decrease fat and increase lean body mass.  GH regulation of 
energy homeostasis and metabolism involves multiple tissues including skeletal 
muscle, liver, and adipose tissue.  GH is classically known as a physiological 
antagonist of insulin action (reviewed in (125)).  The opposing nature of GH and 
insulin is evident by their contrasting influences on adipose cell metabolism 
(126).  When energy produced from nutritional intake surpasses the body’s rate 
of energy expenditure, adipose tissue serves as a repository for excess energetic 
metabolites. Insulin stimulation causes adipocytes to take up glucose and free 
fatty acids (FFA) with conversion to triglycerides for storage, a process known as 
lipogenesis.  GH, on the other hand, has been seen in vivo and in vitro to have 
an opposing effect on adipose tissue.  GH causes the breakdown of triglycerides 
(lipolysis) in adipose tissue and in adipocyte cell culture models and induces 
release of glycerol and FFA (125).  In addition, GH causes adipose tissue to be 
less sensitive to insulin stimulation. Mice deficient in GH are hypersensitive to 
insulin (127).  Mice with excess circulating GH are insulin resistant while 
remaining lean and resistant to high fat diet-induced obesity (128).  Human 
patients with GH excess, including acromegalics (chronic hyperpituitarism often 
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due to a tumor resulting in abnormally high GH secretion) have a high risk of 
developing insulin resistance and type II diabetes (129).  Metabolic effects of GH 
in adipose tissue have been shown to be mediated, at least in part, by changes 
in gene expression (130-133).  A mechanism by which GH is able to influence 
differential gene expression will be investigated in this report. 
 GH influences cell physiology by initiating a signal transduction cascade 
that originates by binding to a dimerized GH receptor (GHR):Janus Kinase 2 
(JAK2) complex.  One molecule of GH binds two molecules of the 
transmembrane GHR, which is thought to facilitate the placement of two 
molecules of JAK2 bound to GHR in an activated confirmation (29, 134, 135).  
JAK2 phosphorylates itself and GHR (29, 40, 136, 137). The resulting phospho-
tyrosines serve as binding sites for downstream adaptor/scaffolding proteins, 
signal transducing kinases, and effector molecules (29, 138-140).  This leads to 
the activation of multiple signaling pathways including IRS-PI3K-Akt (IRS 
interacts with the PH domain of SH2B1 and is recruited to active JAK2 where it is 
tyrosyl phosphorylated (110)), signal transducer and activator of transcription 
(STAT) proteins, and Extracellular Regulated Kinase 1/2 (ERK1/2) (29, 141, 
142).  The activation of these diverse pathways leads to further effector molecule 
modification/regulation and differential gene expression, enabling GH to exert its 
effect in a cell. 
 The adaptor protein SH2B1 is recruited to JAK2 in response to GH binding 
to GHR (22, 29).  There are three members of the SH2B family: SH2B1 (SH2-B, 
PSM), SH2B2 (APS) and SH2B3 (Lnk) (26, 27, 29).  All three family members 
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share the domain structure of a dimerization motif (N-terminal phenylalanine 
zipper), a pleckstrin homology domain, and an SH2 domain, as well as several 
proline-rich domains (reviewed in (29, 39)).  While SH2B1 and SH2B2 are 
ubiquitously expressed in numerous tissues, SH2B3 is mainly expressed in 
hematopoietic tissues (143, 144).  Four isoforms of SH2B1 (alpha, beta, gamma, 
and delta) produced by variable mRNA splicing have been identified.  The four 
isoforms are identical in sequence except for the region downstream of the SH2 
domain.  Variable mRNA splicing confers unique C-terminal sequences for each 
isoform (28, 29).  Recently, the four SH2B1 isoforms have been shown to contain 
a nuclear localization signal (NLS) and nuclear export sequence (NES), which 
have been shown to allow SH2B1β to cycle in and out of the nucleus (29, 66). 
SH2B1 binds to phosphorylated tyrosine 813 on activated JAK2 via its 
SH2 domain and is tyrosyl phosphorylated by JAK2 (29, 40, 42).  Over-
expression of SH2B1 leads to enhanced tyrosyl phosphorylation and activity of 
JAK2.  Enhanced JAK2 activation by over-expressed SH2B1 in COS cells 
expressing GHR has also been shown to lead to enhanced STAT5 tyrosyl 
phosphorylation and activation in response to GH (29, 108).   
SH2B1 may be important for the metabolic regulation of adipose tissue, as 
it has recently been identified as a candidate obesity gene in humans (107) (112) 
and mice (18).  SH2B1β has been implicated in the regulation of actin 
cytoskeleton dynamics (43, 45).  Actin cytoskeletal rearrangements are a 
necessary prerequisite for cellular proliferation, differentiation and migration.  In 
PC12 neuronal cells, SH2B1β has been shown to bind to and activate TrkA, the 
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receptor for nerve growth factor (NGF) (31), and promote NGF-induced neuronal 
differentiation in part by enhancing the expression of a sub-set of NGF induced 
genes required for neuronal differentiation (67).  The NLS of SH2B1β allows it to 
traffic through the nucleus, and this nuclear-shuttling of SH2B1β is required for 
the enhancement of NGF-induced gene expression and differentiation (62).  
Thus, SH2B1 plays a role in the nucleus to regulate differential gene expression 
to mediate the cellular effects of NGF in PC12 cells, including neurite outgrowths. 
3T3-F442A fibroblasts are a murine pre-adipocyte model cell line, which 
are able to differentiate into mature adipocytes that are highly sensitive to GH 
and have been used to characterize the metabolic effects of GH on adipocyte 
biology (145).  SH2B1 has been shown to be required for GH-induced actin 
cytoskeleton rearrangement in 3T3-F442A pre-adipocytes.  It interacts, directly or 
indirectly, with the small GTPase Rac, a known regulator of the actin 
cytoskeleton, and potentially Rac effector molecules in response to GH (29, 43, 
45, 146).  Because nuclear SH2B1 is important for NGF-induced gene 
expression in PC12 cells, there may be additional methods by which SH2B1 acts 
to mediate the effects GH, including direct regulation of gene transcription in the 
nucleus.  In this report, we investigate the effects of SH2B1 on the regulation of 
GH-induced gene expression in 3T3-F442A adipocytes, with a particular 









Methods and Materials 
 
Antibodies and reagents.  Polyclonal antibody to SH2B1 (1:1000) (110) 
was a kind gift from Dr. Liangyou Rui (University of Michigan, Ann Arbor, MI).  
Tubulin antibody (1:1000) is from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA).  IRDye800-conjugated anti-GFP, IRDye700 and IRDye800 conjugated anti-
mouse and anti-rabbit IgG (Rockland Immunochemicals, Gilbertsville, PA) were 
used at a dilution of 1:20,000.  Recombinant 22,000-Da human GH was a kind 
gift from Eli Lilly & Co. (Indianapolis, IN). 
Plasmids.  Rat SH2B1β (NM_001048180) was cloned into the pEGFP C1 
vector (Clontech, Mountain View, CA) (described previously (62)).  Mutations 
were introduced using the QuickChange Mutagenesis kit (Stratagene) and have 
been described previously (62).  To knock-down expression of SH2B1, the 
sequence targeting SH2B1: 5’-CATCTGTGGTTCCAGTCCA-3’ was annealed 
and subcloned into pSuperior.retro.puro (Oligoengine, Seattle, WA) at BglII and 
XhoI sites. A control sequence of 5’-UUCUCCGAACGUGUCACGU-3’ with no 
known target (QIAGEN- Xeragon, Germantown, MD) was also cloned into the 
same vector.  
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Cell culture and cell lines.  The stock of murine 3T3-F442A pre-
adipocytes was kindly provided by H. Green (Harvard University, Cambridge, 
MA). 3T3-F442A fibroblasts were stably transfected by retroviral infection.  
Retroviral infection was performed according to Erickson et al. (147). In brief, the 
recombinant plasmids were transfected into HEK 293T cells by calcium 
phosphate co-precipitation together with the viral packaging vectors SV-E-MLV-
env and SVψ-E-MLV (148). Virus-containing medium was collected 16 h after 
transfection and passed through a 0.45-µm syringe filter.  Polybrene was added 
to a final concentration of 8 µg/ml. This medium was then applied to sub-
confluent (~30%) 3T3-F442A cells. The infection protocol was repeated twice 
with intervals of 16 hours. When cells achieved approximately 80% confluence, 
they were trypsinized, and cells expressing SH2B1 shRNA were stably selected 
in medium containing 2 µg/ml puromycin. 
Microarray.  RNA from murine 3T3-F442A stable cell lines was hybridized 
to Affymetrix Mouse Genome 430 2.0 Array gene chips.  Hybridization and 
analysis of microarray results were conducted in conjunction with the University 
of Michigan Comprehensive Cancer Center’s Affymetrix and cDNA Microarray 
Core Facility with supplemental funding provided by the Michigan Diabetes 
Training and Research Center (grant numbers 5P60 DK20572 & P30-CA46592). 
Cell lysis and immunoblotting.  Cells were solubilized in sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample lysis buffer (50 
mM Tris [pH 7.5], 1% SDS, 0.001% bromophenol blue, 10% glycerol, 0.1% Triton 
X-100, 150 mM NaCl, 2 mM EGTA) and proteins were separated by SDS-PAGE.  
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Proteins in gels were transferred to a nitrocellulose membrane and detected by 
immunoblotting with the indicated antibodies.  Blots were then incubated with 
infrared dye-conjugated secondary antibodies and visualized using the Odyssey 
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). 
qPCR.  Total RNA was isolated using Stat60 (Tel-Test) and cDNA was 
generated using TaqMan Reverse Transcription kit (Applied Biosystems, 
Branchburg, NJ).  Gene expression was assessed using SYBR green I and the 
iCycler system with iCycler iQ Real Time Detection System software (Bio-Rad).  
Amplicons generated from each primer pair were 50–52 bp. The PCR well 
volume of each sample was normalized with fluorescein. All readings were 



















Microarray analysis.  Previously, SH2B1β has been seen to enhance the 
expression of a sub-set of NGF-induced genes in PC12 neuronal cells through 
microarray analysis (67).  This sub-set of genes that have enhanced NGF-
induced expression in cells overexpressing SH2B1β contains genes previously 
identified to be important for neuronal differentiation.  Decreased gene 
expression was seen in response to NGF when SH2B1 was knocked down.  We 
asked whether SH2B1 is having a similar effect on GH-induced gene expression 
in adipose cells.  To gain insight into the function of SH2B1 in adipocytes, we 
carried out microarray analysis of GH-sensitive genes in 3T3-F442A adipocytes 
expressing a non-targeting control shRNA (3T3-F442A-shControl) or shRNA to 
SH2B1 (3T3-F442A-shSH2B1), before and after 1 h GH treatment (500 ng/ml) 
(FIG. 5.1).  When the probe sets on the Affymetrix Mouse Genome 430 2.0 Array 
were re-mapped to represent only distinct genes, out of 16,361 total genes, 611 
genes were up-regulated by GH by at least 60%. Of these 611 genes, the GH 
induction of 274 genes was reduced by at least 66% in 3T3- F442A-shSH2B1 
cells vs. 3T3-F442A-shControl cells (FIG 5.2.). 120 genes fulfilled the more 






shControl   shSH2B1  
FIG. 5.1. SH2B1 expression knocked-down by shRNA.  Stable expression of 
shRNA to SH2B1 (shSH2B1) in 3T3-F442A cells reduced SH2B1 levels by 





16,361  total  genes  
611  (3.7%)  induced  by  GH  at  least  60%  
247  (40.4%)  GH-­induced  expression  
is  66%  or  less  in  shSH2B1  compared  
to  shControl  cells  
FIG. 5.2. Knock-down of SH2B1 decreases expression of 247 GH-
dependent genes.  3T3-F442A cells stably expressing shControl or shSH2B1 
were differentiated into adipocytes, serum-deprived overnight, and incubated 
with 500 ng/mL GH for 1h. mRNA was isolated and analyzed using Affymetrix 
Mouse Genome 430 2.0 chip. 
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with GH-induction reduced by at least 50% in 3T3-F442A-shSH2B1 cells 
compared to control 3T3-F442A-shControl cells.  
Gene expression analysis by qPCR.  To validate the results of the 
microarray, was performed to analyze expression levels of a select set of genes 
in 3T3-F442A cells in response to GH with or with SH2B1 knocked down.  3T3-
F442A-shControl or 3T3-F442A-shSH2B1 cells were differentiated to adipocytes 
and treated with GH for 2 hours.  Total RNA was then isolated and expression of 
the genes most highly up-regulated by GH identified in the microarray study was 
assessed by qPCR.  In 3T3-F422A adipocytes, we have confirmed a 
corresponding ~50% reduction in GH-induced expression in the shSH2B1 cells 
for the genes apelin and Cish (FIG. 5.3).  Apelin and Cish were highly expressed 
in response to GH in 3T3-F442A-shControl cells and this GH-induced expression 
was significantly reduced in 3T3-F442A-shSH2B1.  We were able to confirm the 
GH-stimulated, but not the SH2B1-dependent expression of several other genes 
from the microarray study. 
The gene Arid5a was identified through the microarray as being up-
regulated by GH and dependent upon SH2B1 for its full GH-induced expression 
in adipocytes.  However, Arid5a is more highly expressed in the pre-adipocyte 
state and detectable differences in gene expression were only seen from 3T3-
F422A pre-adipocytes.  Undifferentiated 3T3-F442A-shControl and 3T3-F442A-
shSH2B1 cells were treated with GH for 1 hour and expression of Arid5a was 
analyzed by qPCR.  Arid5a expression was up-regulated in response to GH in 




FIG. 5.3. Knock-down of SH2B1 decreases GH-dependent expression of 
Apelin and Cish.   3T3-F442A preadipocytes stably expressing shControl and 
shSH2B1 were differentiated into adipocytes, serum-deprived overnight and 
incubated with 500 ng/mL GH for 2h.  mRNA levels were determined using 
qPCR, normalized to levels of GAPDH mRNA and then to the gene expression 
in GH-treated shControl cells.  Means ± SEM (Apelin, n=3) or range (Cish, n=2) 
for different RNA preparations are shown. 
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decreased in 3T3-F442A-shSH2B1 cells.  When SH2B1 WT was reintroduced 
into 3T3-F442A-shSH2B1 pre-adipocytes, full GH-induced expression of arid5a 
was rescued, with expression levels similar to those seen from 3T3-F442A-
shControl cells (FIG. 5.4). 
SH2B1 with a mutated NLS does not enhance GH-induced gene 
expression to the same extent as SH2B1 WT.  To determine the role of 
nuclear SH2B1 in GH-induced gene expression, 3T3-F442A pre-adipocytes 
transiently expressing GFP, GFP-SH2B1β WT, or GFP-SH2B1β mNLS were 
stimulated with GH for 1 hour.  Total RNA was isolated and gene expression was 
analyzed by qPCR.  Cish expression in cells overexpressing SH2B1β WT was 
greatly enhanced over levels seen in control cells.  However, Cish expression 
levels from cells overexpressing SH2B1β mNLS was not enhanced to the same 
extent as with WT (FIG. 5.5).  Similar results were seen with Apelin and Arid5a 













FIG. 5.4. Reintroduction of SH2B1β rescues GH-dependent induction of 
Arid5a mRNA in shSH2B1 expressing cells. (A) 3T3-F442A preadipocytes 
stably expressing shControl or shSH2B1 were rescued with GFP or GFP-
SH2B1β rescue construct. Lysates were blotted with α-SH2B1. (B) These cell 
lines were serum-deprived overnight and incubated with 500 ng/mL GH for 1h. 
The GH-dependent induction of Arid5a mRNA was quantified using qPCR, 
normalized to levels of GAPDH mRNA and then to the gene expression in 




FIG. 5.5. The NLS in SH2B1β is required for maximal GH-induced 
expression of Cish mRNA. (A) 3T3-F442A preadipocytes overexpressing 
GFP, GFP-SH2B1β WT, or GFP-SH2B1β mNLS. Lysates were blotted with α-
SH2B1 and α-Tubulin. (B) The above cell lines were serum- deprived overnight 
and incubated with 50 ng/mL GH for 1h. mRNA levels for Cish were determined 
using qPCR, normalized to levels of GAPDH mRNA and then to levels of mRNA 
in GH-treated GFP-SH2B1β−WT cells.  Means and range of replicates are 








 It has been shown previously that SH2B1β is important for regulating 
cellular functions of NGF and GH.  SH2B1β with an intact NLS is capable of 
enhancing NGF-induced neuronal differentiation, in part by enhancing the 
expression of a sub-set of NGF-induced genes required for neuronal 
differentiation.  We asked whether SH2B1 might play a similar role in adipose 
cells in response to GH.  In this report, we elucidate the role of SH2B1β in GH-
induced gene expression. 
 Through microarray analysis, we identified a sub-set of GH-induced genes 
that are dependent upon SH2B1β for their full GH-induced expression.  We have 
confirmed by qPCR the SH2B1β-dependent GH-induced expression for three 
genes: apelin, arid5a, and Cish. 
Apelin is a small protein hormone that is expressed with its receptor, APJ, 
in adipose tissue, brain, vascular endothelium, heart, lung, and kidney (149). 
Apelin is an adipokine that inhibits insulin secretion in mice, consistent with the 
anti-insulin effects of GH. Apelin promotes angiogenesis (150), which is 
important for the development and hypertrophy of fat depots.  Its expression is 
strongly correlated with fat mass in mouse models and human patients, and 
 118 
interestingly, is regulated by GH, IFN-γ, and insulin (151-154), three ligands 
thought to utilize SH2B1 as a signaling protein (22, 32, 33).   
Arid5a (MRF1) is a member of the ARID (AT-rich interaction domain) 
family of DNA binding proteins, and was first identified as a repressor of the 
hCMV enhancer element, where it binds to its upstream, A+T rich modulator 
sequence (155).  Recently, Arid5a was shown to interact with the transcription 
factor Sox9 to stimulate chondrocyte differentiation (156).  Other ARID family 
member proteins have been shown to be important in regulating growth, 
differentiation, and development (157).  The highly homologous Arid5b is 
important for proper growth and development of mice.  Consistent with Arid5b 
playing a role in GH signaling, Arid5b-/- mice exhibit growth retardation, as well as 
reduced viability and abnormal development of reproductive organs (158).  
Arid5b-/- mice were also lean, with significant reductions in brown and white 
adipose tissues, and resistant to weight gain and obesity when maintained on a 
high-fat diet (159).  This suggests that Arid5b is important for accumulating lipid 
stores and adipogenesis.  Arid5a is ubiquitously expressed with the highest 
expression levels in skeletal muscle, liver and heart, is able to interact with 
several nuclear hormone receptors, and can specifically repress the 
transcriptional activity of estrogen receptors α/β and the androgen receptor (160).  
Cytokine-inducible SH2 protein (Cish) is a member of the suppressors of 
cytokine signaling (SOCS) family whose expression is highly induced by a range 
of cytokines, including GH, and is ubiquitously expressed (161-163). The 
promoter region of Cish contains a STAT-binding sequence and its expression is 
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induced by activation of the JAK-STAT pathway (164). Cish functions in a 
classical negative feedback loop to inhibit JAK-STAT signaling (162, 165). 
We also showed that SH2B1β with a mutant NLS is not capable of 
enhancing GH-induced gene expression to the same extent as SH2B1β WT, 
which suggests that nuclear shuttling of SH2B1 is important for the regulation of 
GH-induced gene expression.  However, while these results were intended to 
determine whether nuclear shuttling of SH2B1β is required for the SH2B1β 
regulation of a sub-set of GH-induced genes, it was later realized that not only 
does mutating the NLS of SH2B1β prevent it from entering the nucleus, SH2B1β 
mNLS also does not localize the PM as the NLS of SH2B1β is a dual localization 
motif (65).  Thus, it may only be that PM localization of SH2B1β (where it 
interacts with GHR/JAK2 to enhance JAK2 activity) is what is required for 
SH2B1β to promote enhanced expression of GH-induced genes.  Nevertheless, 
we can conclude that an intact NLS, which ensures both PM and nuclear 
localization of SH2B1β, is required for the full GH-induced expression of SH2B1-














Summary and Future Directions 
 The overall goal of my thesis research was to elucidate functions of 
different SH2B1 isoforms (particularly alpha, beta, and delta).  One approach 
took advantage of human mutations identified in patients with severe obesity, 
insulin resistance, and maladaptive behavior.  Our lab was particularly interested 
to understand if human mutations in SH2B1 identified in patients with severe 
obesity, insulin resistance, and maladaptive behavior lead to dysfunction of 
SH2B1 protein and how, mechanistically, the human mutation conferred 
dysfunction on SH2B1.  There are four isoforms of SH2B1 that mostly behave 
similar to each other (28), yet there are instances when an isoform displays 
unique properties.  The beta and gamma isoforms are of similar length, typically 
expressed together (112), and have been seen to behave very similarly in 
cellular assays (49).  The alpha and delta isoforms are longer transcripts and 
would include additional human mutations that would not be expressed in the 
shorter beta and gamma transcripts.  However, our lab has seen major 
differences in sub-cellular distribution for these isoforms suggesting there may be 
substantial differences in their function.  Alpha is at the plasma membrane (PM) 
and cytosol but not detected in the nucleus even in the presence of a nuclear 
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export inhibitor.  Beta and gamma have been seen to be present in the PM and 
cytosol and accumulate in the nucleus in the presence of a nuclear export 
inhibitor.  In contrast, delta has a steady-state sub-cellular localization at the PM 
and at the nucleolus.  Thus, we must elucidate the specific cellular functions of 
the separate SH2B1 isoforms in order to understand how the cellular functions of 
specific isoforms are affected by human mutations identified in SH2B1.  The 
effects of the human mutations on the cellular functions of SH2B1 alpha, beta, 
and delta are investigated in this report, with particular attention paid to the 
effects on NGF-induced neuronal differentiation. 
Mutations in SH2B1 were identified in patients with hyperphagic obesity, 
extreme insulin resistance, and maladaptive behavior.  The phenotype of the 
human patients closely resembles that of the SH2B1-KO mouse where systemic 
leptin resistance is thought to be a primary factor leading to obesity (18).  Due to 
the fact that the phenotype of SH2B1-KO mouse can be ameliorated with 
transgenic expression of SH2B1 mainly in neurons (54) and that SH2B1 is 
important for neuronal differentiation and survival (30, 31), we investigated the 
effects of the human mutations on the function of SH2B1β in a neuronal context.  
The human and rodent phenotypes would suggest that mutant SH2B1 is 
disrupting leptin signaling.  However, no difference in the ability to promote JAK2 
activation or leptin-stimulated (and insulin-stimulated) IRS2 tyrosyl 
phosphorylation was detected between WT and mutant SH2B1β.  We did detect 
impairment, however, in the ability of mutant SH2B1β to enhance NGF-induced 
neurite outgrowth and GH-induced macrophage migration compared to SH2B1β 
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WT.  While signaling at the level of the plasma membrane does not appear to be 
affected by the human mutations, proper migration and differentiation of neuronal 
precursor cells may be impaired in patients with mutations in SH2B1.  However, 
our assays relied on overexpression of leptin receptor, IRS2 and SH2B1 in 293T 
cells that may have masked any subtle differences in leptin-induced IRS2 tyrosyl 
phosphorylation.  The human mutations may also be affecting other actions of 
leptin that were not measured in this report.  The effect of SH2B1 with human 
mutations on leptin signaling should be investigated in primary neurons that 
express endogenously the leptin receptor.  It may be that leptin neuro-endocrine 
signaling is still disrupted by improper development or maintenance of neurons 
necessary for mediating the effects of leptin and improper neuronal development 
may also explain the cognitive and behavior abnormalities associated with the 
human mutations in SH2B1. 
In order to elucidate the role of SH2B1 in neuronal development, SH2B1-
KO mice will be made that transgenically express WT or mutant SH2B1β in 
neurons in an inducible manner.  I would expect that mice that express 
transgenic neuronal SH2B1β from inception would not develop an obese 
phenotype.  I would expect transgenic mutant SH2B1β expressed at any time 
point before or subsequent to birth, to not be able to protect against the obese 
phenotype.  A finding that postnatally expressed SH2B1β is able to rescue the 
obese phenotype would suggest that SH2B1 is not required from inception for 
proper neural development and raises the question of whether impaired leptin 
signaling is the primary factor causing hyperphagia in SH2B1-KO mice.  SH2B1-
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KO mice do not respond to exogenous leptin administration by reducing food 
intake and body weight (18), implying that leptin signaling in leptin receptor-
expressing neurons is severely disrupted.  This would also suggest that 
therapeutic treatment that increases the activity of leptin downstream of SH2B1 
in human patients, like MC4R agonists or inhibitors of NPY or AgRP function, 
might be a viable approach to treat obesity in the patients with mutations in 
SH2B1.  Expressing the alpha, gamma, and delta isoforms in the animals 
similarly to SH2B1β would help elucidate whether the different SH2B1 isoforms 
have overlapping and/or unique functions during neuronal development.  
 The neuronal assays utilized throughout this report focus on the effect of 
SH2B1 on NGF signaling in PC12 cells.  SH2B1 has also been shown to interact 
with the activated receptors for BDNF and GDNF (30, 35, 64).  Investigating the 
role of SH2B1 in BDNF signaling is particularly relevant for these studies 
because genetic variations that cause reduced BDNF or TrkB expression or 
activity lead to hyperphagia and obesity in humans and mice (13, 14, 166-169).  
To support a role for SH2B1 in neuronal development, neuronal signaling and 
development assays using BDNF or GDNF and cortical precursor cells (or other 
primary neuronal tissues) will be conducted.  Dysfunction in these assays with 
mutant SH2B1 would broaden the scope of where SH2B1 with human mutations 
are having an effect on neuronal function from just NGF signaling. 
Although SH2B1α has been reported to behave similarly to SH2B1β in 
promoting mitogenesis and insulin receptor activity (28, 49), we did not see 
SH2B1α enhance NGF-induced PC12 cell neuronal differentiation as we saw 
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with SH2B1β.  Obese patients with mutations that would only be expressed in the 
alpha isoform do not exhibit the maladaptive behavior phenotype.  Preliminary 
results also suggest that human mutations unique to SH2B1α do not affect GH-
induced macrophage motility (44).  This evidence would suggest that SH2B1α 
does not play an important role in neuronal development, yet patients with 
mutations in the alpha isoform are still obese and insulin resistant.  SH2B1α was 
shown to enhance insulin receptor activity to a greater extent than other SH2B1 
isoforms (49).  We showed that insulin-stimulated IRS2 tyrosyl phosphorylation is 
not affected by human mutations in SH2B1α, yet the nature of this assay with the 
overexpression of SH2B1α and IRS2 may mask any subtle differences in 
phosphorylation.  Human mutations in SH2B1α may be affecting other actions of 
insulin we did not measure in this report. 
If insulin signaling is in fact affected by human mutations in SH2B1α, we 
may be able to see differences in assays measuring other responses to insulin.  
Insulin-sensitive cells, such as 3T3-L1 adipocytes, will be transfected with cDNA 
encoding for WT or mutant SH2B1α, treated with a low concentration of insulin 
(0.1-10 nM), and assayed for glucose uptake, amino acid transport, glycogen 
synthesis, and lipogenesis.  If a dysfunction is observed in any of these assays 
with mutant SH2B1α versus WT, the signaling molecules important for the 
regulation of this response to insulin will be investigated.  I would expect that the 
IRS-PI3K pathway would not be affected based on previous results, however that 
does not exclude downstream effectors or parallel signaling pathways from being 
affected.   
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 While insulin-signaling potentiation may be an important role for SH2B1α, 
it would still appear that SH2B1 activity in the brain is sufficient to maintain 
whole-body energy homeostasis (54).  To further elucidate a neuronal role for 
SH2B1α, it would be key to first learn where in the brain SH2B1α is being 
expressed.  Based on the specific tissues or cell types identified, specific assays 
to test WT or mutant SH2B1α function will be employed.  One example assay 
could be to measure conductance in nerve tissue where SH2B1α would be 
normally expressed between WT and mutant SH2B1α.  SH2B1α maybe affecting 
ion channel or synapse function.   
 I showed that SH2B1δ localized to the nucleus/nucleolus through its C-
terminal bipartite NLS and that this localization is important for SH2B1δ to 
enhance NGF-induced neuronal differentiation.  However, I was unable to 
identify a mechanism by which human mutations in SH2B1δ impair the ability of 
SH2B1δ to enhance neuronal differentiation.  Identifying binding partners of 
SH2B1δ in the nucleus/nucleolus and how the human mutations affect the ability 
of SH2B1δ to enhance neuronal differentiation will further elucidate the role of 
SH2B1 in neuronal development.  
We did not clearly identify the region of the SH2B1δ that is responsible for 
targeting SH2B1δ to the nucleolus.  Our combination of nuclear localization 
signal (NLS) mutations in SH2B1δ did not result in a nuclear but non-nucleolar 
sub-cellular localization of SH2B1δ for any construct tested.  For example, 
SH2B1δ mNLS2 and mNLS3 were present in the nucleolus, however SH2B1δ 
mNLS2/3 was not present in the nucleus at all.  This suggests that while NLS 2 
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and NLS 3 are responsible for nuclear entry of SH2B1δ and could be targeting it 
to the nucleolus, another region may be directing SH2B1δ to localize specifically 
at the nucleolus.  RNA-binding motifs (stretches of aromatic amino acids) and 
glycine/arginine-rich (GR) domains have been implicated in targeting nuclear 
proteins to the nucleolus (124).  The SH2B1δ C-terminal tail contains a Trp-rich 
region as well as GR segments within the bipartite NLS (28).  A series of deletion 
mutants as well as mutations targeting GR segments or the Trp-rich region will 
be used to identify the C-terminal region of SH2B1δ responsible for nucleolar 
localization.  Once this region is identified, forms of SH2B1δ that allow for 
nuclear but not nucleolar localization will be assayed for their capacity to promote 
NGF-induced neuronal differentiation.   
I would expect WT but not nucleolar-excluded SH2B1δ to be able to bind 
RNA and other nucleolar or ribosomal proteins.  It would be interesting to 
compare a global screen of binding partners in response to NGF between 
SH2B1δ WT, non-nuclear SH2B1δ, non-nucleolar SH2B1δ, and SH2B1β.  I 
would expect that I would identify many proteins common to SH2B1δ and 
SH2B1β.  However, differences between interacting partners of SH2B1δ WT and 
non-nuclear/nucleolar SH2B1δ (that presumably would not enhance NGF-
induced neuronal differentiation) may provide great insight into what SH2B1δ 
might be doing in the nucleolus.  Interestingly, when SH2B1β accumulates in the 
nucleus, it appears excluded from nucleoli (112).  This difference in sub-nuclear 
localization may suggest that the beta and delta SH2B1 isoforms are acting to 
regulate neuronal differentiation by different mechanisms.  Identifying differential 
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binding partners of the two isoforms may help elucidate these differing 
mechanisms.    
There are a number of proteins in the nucleus that regulate neurogenesis 
that may be affected by mutant SH2B1 (170).  Phosphorylation in response to 
NGF in cells expressing WT or mutant SH2B1δ will be investigated for proteins 
such as Elk-1, serum response factor (SRF), cAMP response element-binding 
protein (CREB), and ribosomal S6 kinase (RSK).  I would expect phosphorylation 
of one or more of these proteins essential for neuronal differentiation would be 
impaired from cells expressing mutant SH2B1δ compared to WT. 
 It may be that SH2B1δ acts to increase ribosome biosynthesis from 
nucleoli to promote neuritogenesis.  Activation of RNA polymerase I (Pol1), which 
transcribes ribosomal DNA, is sufficient to cause cellular hypertrophy and neurite 
outgrowth in neuronal cells (reviewed in (123)).  Pol1 is activated by transcription 
initiation factor-1A (TIF1A) and TIF1A is activated by phosphorylation on serine 
residues 633 and 649 by ERK 2 and RSK2 (which is activated by ERK 1/2), 
respectively (171).  We have shown that SH2B1δ enhances ERK 1/2 
phosphorylation in response to NGF.  Thus, I hypothesize that TIF1A will be 
more highly phosphorylated in response to NGF from cells expressing SH2B1δ 
WT resulting in increased differentiation compared SH2B1δ with a human 
mutation.  A finding that signaling through TIF1A is not reduced when a human 
mutation is introduced into SH2B1δ, would suggest that impairment of neurite 
outgrowth in response to NGF seen when PC12 cells express SH2B1δ with a 
human mutation is not due to impaired regulation of ribosome biosynthesis. 
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 Through microarray analysis, we were able to identify a subset of genes 
that required SH2B1 for their full GH-induced expression.  We also showed that 
an intact NLS motif (which targets SH2B1β to the plasma membrane and nucleus 
(65)) in SH2B1β is required for SH2B1β to maximally enhance a sub-set of GH-
induced genes.  However, we were unable to conduct the experiments to 
elucidate a mechanism by which SH2B1β regulates gene expression due to time 
constraints.   
I hypothesize that SH2B1β interacts with transcription factors to assemble 
transcription-activating complexes, or acts to shuttle transcription factors that 
repress transcription out of the nucleus to then allow for activation of 
transcription.  Gene Set Enrichment Analysis from the set of SH2B1-dependent, 
GH-induced genes identified a list of transcription factor binding motifs that are 
statistically over-represented in this set (Table 6.1).  Interaction of these 
transcription factors with SH2B1β in response to GH will be assayed to gain  
understanding of how SH2B1β acts in the nucleus to regulate gene expression.  I 
would expect SH2B1β WT, but not SH2B1β mNLS, to interact with one or more 
of these transcription factors to regulate gene transcription.   
 I used proteomics with mass spectrometry to identify binding proteins of 
Flag-tagged SH2B1β in response to GH (Table 6.2).  Confirmation of SH2B1β 
interaction with proteins will be prioritized based on relevance.  I would prioritize 
assaying SH2B1β interaction with signaling proteins Map3k7 and Tab3 (a binding 
partner of Map3k7), as well as RNA-handling proteins like Adar and Sfrs 2/3.  






Fact o r    Sequence  Mot i f   
Total  
gene s   
Hot  
gene s   
NRF1    CGCATGCGCR    155    1 2   
NRF1    RCGCANGCGY   566    2 9   
YY1    GCCATNTTG    279    2 1   
YY1    NNNCGGCCAT  
CTTGNCTSNW   156    1 1   
E2F    NCSCGCSAAAN   161    1 2   
E2F    TTTCGCGC    154    1 1   
OCT1    NNNRTAATNANNN    159    1 2   
PAX 3    CGTSACG    102    9   
FOXO3    TNNTTGTTTACNTW   166    1 2   
HNF 1    DGTTAATKAW  
TNACCAM    166    1 2   
C/EBP   NTTRCNNAANNN    194    1 3   
S R F    SCCAWATAWG  
GMNMNNNN    174    1 2   
I RF    BNCRSTTTCANTTYY   155    1 1   
Over-­represented  transcription  factor  binding  sequence  motifs  with  p-­value  <  0.01.  
N  =  any  nt,  B  =  not  A,  D  =  not  C,  H  =  not  G,  V  =  not  T,  K  =  G/T,  Y  =  C/T,  S  =  C/G,    






Table  6.1.    Identification  of  over-­represented  trancription  
factor  binding  site  sequence  motifs  from  gene  set  enrichment  
analysis  of  GH-­induced,  SH2B1-­dependent  genes.
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and neuronal differentiation.  SH2B1δ localizes at the nucleolus which is a major 
site of RNA processing and several RNA-handling proteins were identified in our 
screen.  The regulation of RNA processing is another mechanism by which 
SH2B1 may be regulating gene expression. 
  Carrying out these experiments will provide important insight into how the 
different SH2B1 isoforms act to regulate cytokine and growth factor signaling and 
how they are affected by human mutations identified in SH2B1.  Further 
understanding of the mechanism of action of SH2B1 may provide basis for 
therapeutic intervention to treat obesity and/or insulin resistance in humans. 
 A schematic summarizing the functions of SH2B1 in response to 
neurotrophic factors and how they are impaired by the human mutations is 
depicted in FIG. 6.1. 
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Table 6.2.  Identification of potential interacting partner of SH2B1.  Flag-
SH2B1β was immunoprecipitated from 3T3-F442A adipocytes after stimulation 
with GH (500 ng/ml) for 1 hour.  Proteins were detected by mass spectrometry 
and an abbreviated list of relevant proteins are presented. 
  
Proteins identified as potential SH2B1-interacting proteins 
Adar (Adenosine deaminases acting on RNA)  
Hdx (Isoform 1 of Highly divergent homeobox)  
Pcbp1 (Poly(rC)-binding protein 1) 
Prpf31 (Isoform 1 of U4/U6 small nuclear ribonucleoprotein) 
Setx (Isoform 1 of Probable helicase senataxin) 
Sfrs2 (Splicing factor, arginine/serine-rich 2) 
Sfrs3 (Isoform Long of Splicing factor, arginine/serine-rich) 
Smad1 (TGF-beta-signaling transcription factor) 
Sub1 (Activated RNA polymerase II transcriptional coactivator) 
Thrap3 (Thyroid hormone receptor-associated protein 3) 
Map3k7 (Mitogen-activated protein kinase kinase kinase 7) 
Tab3 (TGF-beta-activated kinase 1 and MAP3K7-binding protein) 












FIG. 6.1. Schematic of SH2B1 function in response to neurotrophic factors 
and where it is impaired by human mutations.  SH2B1 localizes at the 
plasma membrane and cytosol and cycles in and out of the nucleus.  SH2B1 
acts to enhance NGF-induced gene expression and neurite outgrowth.  It is 
hypothesized that SH2B1 acts to form a transcription-activating complex in the 
nucleus or promotes gene transcription by shuttling a repressor transcription 
factor out of the nucleus or a signaling molecule into the nucleus (ProtX).  
SH2B1 translocation to the nucleus and ability to enhance neurite outgrowth in 





Table 6.3.  Summary of assays presented in this dissertation by isoform of 
SH2B1.  Assays are listed across the top with SH2B1 cDNA used in the assay in 
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